<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
   xmlns:ao="http://www.w3.org/ns/oa#"
   xmlns:dailymed="http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/"
   xmlns:dct="http://purl.org/dc/terms/"
   xmlns:dikbD2R="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/"
   xmlns:domeo="http://www.w3.org/ns/domeo#"
   xmlns:foafx="http://xmlns.com/foaf/0.1/"
   xmlns:pav="http://purl.org/pav/"
   xmlns:permissions="http://vocab.deri.ie/cpo#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
   xmlns:sio="http://semanticscience.org/resource/"
>
  <rdf:Description rdf:about="urn:domeoclient:uuid:390CA5FE-7939-4F69-B612-7F5C21A06481">
    <domeo:belongsToSet>urn:domeoclient:uuid:71CADA90-E1E5-4B50-9394-FDFC0B1512B0</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1085914C-2530-49EB-92B4-1E4BC17AEBAC"/>
    <pav:createdOn>2014-07-13 11:02:05 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 11:02:34 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:9CBDBE67-2211-4254-BEF8-DDC84C5BB035</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2093FF56-689E-4246-AF69-F566860B27BF">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 09:42:25 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:E766D1AC-45BC-4579-89AD-BE0DEC69FC35"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F1DD8EF-72E2-425B-B98B-233F1591A13F">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8F1DD8EF-72E2-425B-B98B-233F1591A13F"/>
    <ao:exact>sildenafil </ao:exact>
    <pav:createdOn>2014-07-07 09:42:06 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:suffix>is 105 L, indicating distribution into the tissues. Sildenafil and its major circulating N-desmethyl metabolite are both approximately 96% bound to plasma proteins. Protein binding is independent of total drug concentrations.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>is taken with a high-fat meal, the rate of absorption is reduced, with a mean delay in Tmax of 60 minutes and a mean reduction in Cmax of 29%. The mean steady state volume of distribution (Vss) for </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8E221E79-602A-4812-8488-538D6506C879">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-13 11:17:48 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:AD57239D-3225-4F0C-8054-FBD32976EE0C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:99FCA5E3-D174-4EE6-A00A-E8CEB0ED9FB4</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A31AAC0C-4709-458E-B722-42176D2F7E8D">
    <ao:suffix> and 9-hydroxyrisperidone combined, after single and multiple doses, are similar in extensive and poor metabolizers.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A31AAC0C-4709-458E-B722-42176D2F7E8D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:13:47 -0400</pav:createdOn>
    <domeo:uuid>A31AAC0C-4709-458E-B722-42176D2F7E8D</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix> concentrations than poor metabolizers, the pharmacokinetics of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D16208CB-7392-415A-8487-52928A419F00">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D16208CB-7392-415A-8487-52928A419F00"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 12:46:12 -0400</pav:createdOn>
    <ao:suffix> 100 mg was administered as a single oral dose alone and two hours after a single dose of cimetidine 400 mg to six healthy male volunteers. After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax. There was a </ao:suffix>
    <ao:exact>Fluconazole</ao:exact>
    <domeo:uuid>D16208CB-7392-415A-8487-52928A419F00</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4A268B82-4B69-4D00-A6E9-95F225012877">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:16:15 -0400</pav:createdOn>
    <ao:suffix> to the enzyme suggests this is unlikely [see 7 DRUG INTERACTIONS].</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <domeo:uuid>4A268B82-4B69-4D00-A6E9-95F225012877</domeo:uuid>
    <ao:prefix> to interfere with metabolism of other drugs metabolized by CYP 2D6. Relatively weak binding of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4A268B82-4B69-4D00-A6E9-95F225012877"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1230CFBE-6F41-4107-8D50-5F5A730D40C5">
    <ao:exact>Risperidone</ao:exact>
    <pav:createdOn>2014-07-13 11:07:49 -0400</pav:createdOn>
    <domeo:uuid>1230CFBE-6F41-4107-8D50-5F5A730D40C5</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> has low to moderate affinity (Ki of 47 to 253 nM) for the serotonin 5HT1C, 5HT1D, and 5HT1A receptors, weak affinity (Ki of 620 to 800 nM) for the dopamine D1 and haloperidol-sensitive sigma site, and no affinity (when tested at concentrations &gt;10-5 M) </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1230CFBE-6F41-4107-8D50-5F5A730D40C5"/>
    <ao:prefix> acts as an antagonist at other receptors, but with lower potency. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97FF727B-70F7-4A8F-9355-6D53C2602A7E">
    <pav:createdOn>2014-07-13 11:13:47 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A31AAC0C-4709-458E-B722-42176D2F7E8D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:7226510B-6369-4D4F-859D-276E6199315C</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5139C7C3-ACE5-4F03-BC84-8DD2AF187DDB">
    <pav:createdOn>2014-07-07 11:22:50 -0400</pav:createdOn>
    <ao:suffix>(800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5139C7C3-ACE5-4F03-BC84-8DD2AF187DDB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Cimetidine </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2ABA1A35-6C77-4A0A-9EC5-109AA13136B6">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 09:58:59 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D3737933-330F-487F-B41C-CDB0FF5C6F1C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:6129321F-FF20-473A-89DA-A79D75F63074</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2F71B86E-3B80-4813-9F00-A9E3E6B30C9E">
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-07 09:39:26 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:EAE26632-A8D8-4E80-ADE1-8902853460F6"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:92530361-A562-40CE-942A-CC181EBE7AD7">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 12:34:42 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 12:34:35 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:6A05795B-B1AB-4DB3-A12F-2765CBCC2FED</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:A22D7450-FC77-45A4-B835-3948870AD344"/>
    <pav:lineageUri>urn:domeoserver:annotation:FB9B5330-BB9D-4DA0-8780-703069BE2890</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B85AE85-A07C-4614-91F5-52EF7A4737DF">
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3E08DAB4-201F-48CD-8ACA-375750DA65B1"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:3BDF4B68-5BF9-4914-96AA-D5E7665E8769</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-07 11:22:56 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2532730F-81C6-4CC5-93B2-FC3A19B98EC5">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:2080DF37-EAA6-443D-A391-2897A81CAD23</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:FA839309-7C8B-4446-A5C1-08694E7B8482"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:09:57 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3EBDA2ED-165F-4B57-B4BE-CFA63CD5C5A6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Sildenafil</ao:exact>
    <ao:suffix>, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation. In patients with pulmonary hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemi</ao:suffix>
    <ao:prefix>(PDE5) in the smooth muscle of the pulmonary vasculature, where PDE5 is responsible for degradation of cGMP. </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-07 09:36:02 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3EBDA2ED-165F-4B57-B4BE-CFA63CD5C5A6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:420B9B73-0394-4975-8634-61202EA8F217">
    <ao:context rdf:resource="urn:domeoclient:uuid:83D060E5-70B4-4270-94D2-6FF812E77E78"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:F0B97FA3-5873-4BED-A500-3F99EF51951C</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 11:12:03 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2BF9F224-82C0-470E-9645-8A6965E66A04">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> The mean increase in</ao:suffix>
    <domeo:uuid>2BF9F224-82C0-470E-9645-8A6965E66A04</domeo:uuid>
    <ao:prefix> 50 mg once daily for 10 days in 10 healthy women. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2BF9F224-82C0-470E-9645-8A6965E66A04"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <ao:exact>There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole.</ao:exact>
    <pav:createdOn>2014-07-13 12:45:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CBB863B4-0141-4362-8357-0FD5A3909A10">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:098AA784-6695-4935-9450-C87D502EDBCD"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:23A67AAE-576A-4FB5-8468-E2C34B2748CB</pav:lineageUri>
    <pav:createdOn>2014-07-07 11:23:07 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA">
    <ao:item rdf:resource="urn:domeoclient:uuid:9BD9047F-C1DA-4B64-92B7-4D031972C9CF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DA7B78BE-B91C-4178-9AF1-7DC800EF5121"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1F12731E-6D41-4E27-83E3-C87822424FCA"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:10BB95F9-1856-4D70-9976-235CE8AD3D39"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3ED57AC4-296D-4C8D-9873-49C193F69BBA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:79293219-D172-4E27-A045-D16B4F539C60"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2CF891F7-2E96-4382-8EDB-5C061E8E1AFA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:735CA4BD-A16D-4729-BFC3-96D72BFE5B0B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E5DE379E-8BB3-4609-BFC6-A0E275978ADC"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <permissions:permissions rdf:nodeID="N194479db07e844a3abef316ba99c1dab"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:54B9529D-9030-4194-B66A-D7ECCBABED1F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9E010F58-AD7C-435C-B2DC-0F81F34B978E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8C5BA635-EF8B-4165-A2A6-5832D61A15BF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:222C9B55-A770-41C7-AF04-566E7C7A1DBC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DC9FB0B5-1564-4BF2-A4E4-4D05B0A1AB86"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5D480921-AA61-499B-9C3F-3043269104B4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6588D45E-2F4C-40CF-8AF4-0CD621F484E1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:697C8F03-1543-4427-9D85-7967FCEA3100"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FB0C633B-9063-4FD0-91E9-2810CF1C157A"/>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:55E300CE-2A8F-42F4-9877-A49DDE4F3360"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DE5C582E-1F4C-478C-9DDC-DAB4C0C1ABFF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2093FF56-689E-4246-AF69-F566860B27BF"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:7D37CC60-618E-46B6-8C99-BA7D598E3762"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:02D92735-6D44-4DFA-A2E9-75A5A3D4DCF9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3B85AE85-A07C-4614-91F5-52EF7A4737DF"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:137A1951-AA86-4074-9581-B011801B955F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BDA75ADA-742A-402B-AE97-4438F99C61FC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2ABA1A35-6C77-4A0A-9EC5-109AA13136B6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FA428F64-D782-46F5-B866-2FBC24D3F4F8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B8D94772-B85A-452F-91A5-C644F8298C08"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0B2918C2-A28D-40C3-8147-F19D09B7119C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B9E21C61-063D-4F80-8E08-85865B387669"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E7907DD5-4FA4-4B5A-99D9-9D24B76931C6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:42423629-C409-4AD4-BBE6-7C86A696F03E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6FD9D48D-F639-4F09-ABA6-F4B259681453"/>
    <pav:previousVersion>urn:domeoserver:annotationset:22ED7220-C6F6-43C5-9DF9-89F62F0F8E27</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:CBB863B4-0141-4362-8357-0FD5A3909A10"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2F71B86E-3B80-4813-9F00-A9E3E6B30C9E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FA4C8A6E-17D4-47F8-A369-67AF061E9037"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F3C4287B-36A9-48BF-8081-A39BEF5F3C51"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E76D782E-ADBF-42D0-9CCA-8944F07D22DA"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3762570C-CF43-4DB9-B163-FAA6DAE60017"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2014-07-07 11:37:25 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-07 09:34:12 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:B5E75366-F0BF-442F-852E-19C5EDDC84EE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:74FDA5BD-9C18-4F10-AC59-C5C75AA497C2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:57E98049-37B0-4F70-963B-F0D12C3B36C7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1C02BE13-5688-4657-A7A7-6A459283AEB2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C8D05CE4-8287-449A-8921-AFACBAEE2002"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3D22E6FA-B90D-49C2-B42F-B8122D48D82A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E0DCF362-11F8-4FF3-8C3C-EDB9DD3D53A7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:08713DDF-0935-4B63-B281-AEE56A8D7628"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:16393981-08BF-477D-ACB9-8FB804E50D0C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8ABD9FDA-0F08-474A-A9C8-437A5346F2AC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EC416A29-1315-42C5-90FA-652412A6AD12"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE16BF01-AD42-444E-9A68-FEF6AED26815"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E76B5D64-7248-4EBD-A023-3820BFDEFD26"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F9FE917E-CAFF-4C8B-B16B-BB0606212145"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E13140FE-59B4-45B2-A524-CAED051C4F9D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:32B1CD5D-3CD7-4D5E-BD76-57F6F0A9480A"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:17E64297-0A57-4C9B-94C4-18ED1956FCF7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:211F5FD6-FC29-4AC5-96E1-14E088108ABB">
    <ao:suffix> (See PRECAUTIONS.</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Administration of a single oral 200 mg dose of fluconazole after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <domeo:uuid>211F5FD6-FC29-4AC5-96E1-14E088108ABB</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:211F5FD6-FC29-4AC5-96E1-14E088108ABB"/>
    <pav:createdOn>2014-07-13 12:56:54 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5672F5D0-071A-4DE9-9A98-BD20431A00C2">
    <domeo:uuid></domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-07 09:34:12 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5672F5D0-071A-4DE9-9A98-BD20431A00C2"/>
    <ao:exact>Sildenafil </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>is an inhibitor of cGMP specific phosphodiesterase type-5 (PDE5) in the smooth muscle of the pulmonary vasculature, where PDE5 is responsible for degradation of cGMP. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells res</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5FF2B43E-5E15-4C21-BFDD-C97D4C18B3B1">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:C2EEFE36-AE7E-4BF4-943E-03D2760C673E"/>
    <pav:lineageUri>urn:domeoserver:annotation:28D6D7F6-0FFB-41F2-BC7C-A9F0E4ED53AC</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 11:08:45 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DFCBEAF2-DEEA-4C46-A167-B2B6F5C56C00">
    <ao:context rdf:resource="urn:domeoclient:uuid:49F82F74-6EDD-4994-8052-10CB1FCA4BA0"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:09:11 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:AB8C215A-FA3F-4A34-A334-0F1287CE0DA8</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A0EE858B-D738-4E79-B01E-E50A3141586B">
    <ao:prefix> [see 7 DRUG INTERACTIONS]. This occurs with </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:15:01 -0400</pav:createdOn>
    <domeo:uuid>A0EE858B-D738-4E79-B01E-E50A3141586B</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>quinidine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A0EE858B-D738-4E79-B01E-E50A3141586B"/>
    <ao:suffix>, giving essentially all recipients a </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:804C4BF7-B45B-4CC2-BD44-707AAD50F219">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:11:13 -0400</pav:createdOn>
    <domeo:uuid>804C4BF7-B45B-4CC2-BD44-707AAD50F219</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:804C4BF7-B45B-4CC2-BD44-707AAD50F219"/>
    <ao:suffix> nor 9-hydroxyrisperidone displaces each other from plasma binding sites. High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidon</ao:suffix>
    <ao:exact>risperidone</ao:exact>
    <ao:prefix>, is 77%. Neither </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F31EE1EC-A22F-4FE9-8763-7C623AD7B0BE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <domeo:uuid>F31EE1EC-A22F-4FE9-8763-7C623AD7B0BE</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F31EE1EC-A22F-4FE9-8763-7C623AD7B0BE"/>
    <pav:createdOn>2014-07-13 11:08:54 -0400</pav:createdOn>
    <ao:suffix> and its major metabolite, 9-hydroxyrisperidone [see 12 CLINICAL PHARMACOLOGY]. Antagonism at receptors other than D2 and 5HT2 [see 12 CLINICAL PHARMACOLOGY] may explain some of the other effects of risperidone.</ao:suffix>
    <ao:prefix> results from the combined concentrations of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B06BD29E-2481-4EA0-885B-420749EBE703">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B06BD29E-2481-4EA0-885B-420749EBE703"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <domeo:uuid>B06BD29E-2481-4EA0-885B-420749EBE703</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>fluconazole</ao:exact>
    <ao:suffix> AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from o</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, there was a significant decrease in </ao:prefix>
    <pav:createdOn>2014-07-13 12:46:20 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DA7B78BE-B91C-4178-9AF1-7DC800EF5121">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:B08B644F-5630-4DD4-870A-83EE4BFF9279</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-07 11:22:50 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5139C7C3-ACE5-4F03-BC84-8DD2AF187DDB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55C36B4E-CDCE-4B16-94D5-178014A48A7F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <domeo:uuid>55C36B4E-CDCE-4B16-94D5-178014A48A7F</domeo:uuid>
    <ao:suffix>, its major metabolite, 9-hydroxyrisperidone, and risperidone plus 9-hydroxyrisperidone are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily). Following oral administration of solution or tablet, mean peak plasma conce</ao:suffix>
    <ao:prefix>Plasma concentrations of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:55C36B4E-CDCE-4B16-94D5-178014A48A7F"/>
    <pav:createdOn>2014-07-13 11:09:28 -0400</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6588D45E-2F4C-40CF-8AF4-0CD621F484E1">
    <pav:lineageUri>urn:domeoserver:annotation:905A65BE-2FB4-442E-92C6-EA5747341AA6</pav:lineageUri>
    <pav:createdOn>2014-07-07 09:58:43 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:FAD17173-A1D3-4A24-A29E-5999F0DFA8F4"/>
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A0AE7AB-260B-4296-BC83-DB443FEE5161">
    <ao:prefix> AUC and Cmax. There was a mean ± SD decrease in </ao:prefix>
    <ao:suffix> AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of flucon</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>6A0AE7AB-260B-4296-BC83-DB443FEE5161</domeo:uuid>
    <pav:createdOn>2014-07-13 12:46:24 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <ao:exact>fluconazole</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6A0AE7AB-260B-4296-BC83-DB443FEE5161"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C5594C9A-8B88-4CF6-B5AA-3F081580D92D">
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:3F11C6A1-A35B-4B78-8E4B-F4E54C9EB08B</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:13:40 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8543469A-E725-45C1-A0A3-93FAB55D1DD5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35685454-E730-4B12-A923-46EE9655234C">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:2703BC23-B5BF-482E-A701-F416ADF738D1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:AB3EAD78-45A5-439B-B26A-FE0BB9EDCBD0"/>
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-13 12:56:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:962DC691-3D08-4224-8D22-C0DD8D9F24CA">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 12:56:00 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:4EAFAB1D-1E62-4401-9065-8F44961694A1</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:0F95BD67-87EE-4AA9-A33E-A0BCF7921FF0"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232">
    <ao:item rdf:resource="urn:domeoclient:uuid:4019A76A-1D16-4F04-8CBF-FF855DD2A7A2"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:E73E8FF7-7FA2-47F3-B0B1-14D1640DDBF7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0025BED1-B4CA-4D8F-9C43-B2F10841CCF4"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:017A9836-D985-4347-BFF0-9EBED8DB5CD1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:90F5AA7B-F35E-4B00-A666-C6FE8F1B0324"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:420B9B73-0394-4975-8634-61202EA8F217"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:64792593-BEAB-4B65-88FB-A2254663F469"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:56F428F6-CAF7-4343-B57C-103B1BA935EB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EFBA3663-4C52-45BA-895B-7EB3C0A4DA3A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:99E97745-423E-4818-BFC6-3F67C8BF2A87"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:C15235C1-3B10-4949-B8E4-1D7FCCD3AC4B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:05BFBD66-D24D-4F61-89C5-4EDDE7B6040C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:97C1D6A3-E462-4C1F-8DD6-513D5AD2268A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5BA6BC8B-1F30-4288-9D03-060F552BAA12"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:539264FC-F626-408A-BB71-03BC387083CB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:934B866B-AFCB-4F4A-A5CA-1B312B3088E1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:14556CC1-0C55-47A6-8175-973C292639CC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:94239CD6-2883-459B-A125-FF55B9791833"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8EAC93E7-05D8-439B-86B4-7B47CB07E8D8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2532730F-81C6-4CC5-93B2-FC3A19B98EC5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:34472B29-EA4E-45E5-84B2-2EEE556610B6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3805F006-2423-4B51-87AB-CAE85C6B4E21"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FD9D4BD5-A390-4CD6-8FF4-21ABE76D596A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B9C5564E-F653-404D-B333-299E63141AF5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:89155DC0-3493-4590-8DD7-44717F141C27"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5FF2B43E-5E15-4C21-BFDD-C97D4C18B3B1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A46A827E-4936-4BBC-8078-913DD6DAA84E"/>
    <pav:lineageUri>urn:domeoserver:annotationset:90C0A4CD-5288-4960-B31A-195D0159FE45</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:E8680340-7715-4656-A160-A6F608AD7CE9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:518CD4C6-1719-48AB-B300-84A10DEACB68"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2EC8E075-F7E3-4259-A656-99D292E9F0A4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:72584FCC-E5F1-4130-993B-ED469AE3E810"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1E597BBC-9857-4D08-953B-5CBE831F5884"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:92436D94-1FB4-49B2-B20D-385CA961A940"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8B475492-95FE-4CDD-81AE-94DFEEB91E11"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:464ED203-77EC-4EFC-873A-7853A308DCA5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DFCBEAF2-DEEA-4C46-A167-B2B6F5C56C00"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2537CEFB-4053-4AC9-8731-C65B1AC5D0F9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FE717566-90D0-4B59-B00F-B053CAE639C4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9BD1E279-39ED-4853-AF2E-BE56BEB4AF03"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EEC761C8-1050-4E1A-A450-D460F8514160"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E728D92E-FEA6-4EE6-9E40-E59051DEB8E3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CAC294B3-5790-4488-B65C-CB3269F765C6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:454E7688-A4B1-42BF-86B5-6E1A3C88986A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:95AEC430-A2F4-4B0D-B623-70050D7B891E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4E77E45D-0BB8-4168-8CAF-9D1591E37A36"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3B743E18-8323-4761-B0A4-3B200C16F9BE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A6F0B480-ABD4-436B-8A6F-A4BD34827F73"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:72843AE3-90CC-43FD-BCEC-E83B4E3A7EDF"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:3B18CF78-48CD-4D32-B4F4-88F8072C8185"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6B6560EB-DD3A-4FD9-ACE8-690CA260DD8B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:92DB5361-BE2B-4C69-B141-FB431E8EFC22"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6ECE2E9A-54C4-4507-95A6-2F4053719529"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6DDA4ED5-743F-4C12-93A8-37B2366FF364"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:A361190A-A611-4162-AA47-4014AAEBA0B2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7CC41192-004E-44F9-8E3D-0FF7CECF1DC2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:23E5F3F5-E089-460E-A736-58E2FC44ADC6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B088F7FA-8870-4336-965B-4A558E3F08B0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9AF0B949-C133-4703-9F65-362D4B5B4494"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6EC654F2-7C5C-4C0B-9973-518245983B18"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0D7139F9-BDC3-437F-A5A1-D75EDAC972B0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:420A77EC-3CAE-4EA3-B428-B635FA4A9F5D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5F8E4E79-C59A-410E-ACD6-41B9C532F968"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9011E52E-6FAE-42BF-913B-D3EF952E8A2B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:0C4061A3-979D-486B-9CDA-1CFF771CCB5B"/>
    <permissions:permissions rdf:nodeID="N1f266d2bcef44243b32a72d28605a5ee"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5B622988-60A1-49F1-966B-8460BBF1DD4D"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:E6A5356C-B181-4F61-AEF2-74464A340D7F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8E221E79-602A-4812-8488-538D6506C879"/>
    <pav:createdOn>2014-07-13 11:04:07 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:C5594C9A-8B88-4CF6-B5AA-3F081580D92D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CBE541BF-AED9-48E5-ACA0-9309C45B20F5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F0AC105E-C659-4D3F-9F13-4104BCC29CDE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:651C0626-4BF6-4B96-A66A-7385C6456D51"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E2A93D3C-935C-417F-BE1B-282EDBEB8D85"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1C446162-FA92-4715-9095-A116DC12F4C8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A151EB77-7400-49F2-9673-BFAD2171D5CD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:97FF727B-70F7-4A8F-9355-6D53C2602A7E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7AF3A49F-90C3-4D03-97CB-74AE03BF7C86"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9F3CA373-B79A-4B2D-8C96-BFB67CB4B175"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E202AAE6-7DCA-486D-9C29-8CB3B82CFECF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:04EFF21D-F5C9-468D-BFA5-057DD08ABD00"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CA230F0A-406C-43AE-88DE-A7FD67CF4D61"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:71E5047C-5690-4D45-9A6E-FB1384C14928"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F94384BA-7A08-4E0D-A89C-A73959BAA203"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BA2C0A64-143A-46D5-A408-01FC3EC62525"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F46BEE2C-B82E-4386-96D7-C74221898C04"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C0F812BF-119E-4BE1-AAA3-BF2DAE39B76F">
    <ao:suffix>is selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, &gt; 80-fold for PDE1, &gt; 700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11). The approximately 4,000-fold selectivity for PDE5</ao:suffix>
    <pav:createdOn>2014-07-07 09:36:31 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>sildenafil </ao:exact>
    <ao:prefix>Studies in vitro have shown that </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C0F812BF-119E-4BE1-AAA3-BF2DAE39B76F"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E0DCF362-11F8-4FF3-8C3C-EDB9DD3D53A7">
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:206422C6-3F3C-47E8-AC4D-3CADF0982F38</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-07 11:22:54 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:3A07EF3E-A1DF-4E0E-952B-5422EC6E9B3D"/>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76B68D47-1D9C-4B2A-B9A6-CFE359C93E64">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>fluconazole</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <ao:prefix>. There was a mean ± SD reduction in </ao:prefix>
    <pav:createdOn>2014-07-13 12:56:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:76B68D47-1D9C-4B2A-B9A6-CFE359C93E64"/>
    <domeo:uuid>76B68D47-1D9C-4B2A-B9A6-CFE359C93E64</domeo:uuid>
    <ao:suffix> AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours. (See PRECAUTIONS.)</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0CCA954-EB0E-4D16-9B00-C1E4BE4A989D">
    <ao:suffix>AUC.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-07 11:24:14 -0400</pav:createdOn>
    <ao:exact>sildenafil </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F0CCA954-EB0E-4D16-9B00-C1E4BE4A989D"/>
    <ao:prefix>Cmax and a 210% increase in </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:49F82F74-6EDD-4994-8052-10CB1FCA4BA0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:09:11 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>49F82F74-6EDD-4994-8052-10CB1FCA4BA0</domeo:uuid>
    <ao:suffix> is well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.</ao:suffix>
    <ao:prefix>Absorption: </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:49F82F74-6EDD-4994-8052-10CB1FCA4BA0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611">
    <ao:item rdf:resource="urn:domeoclient:uuid:60E67B22-5DBF-4F42-9120-BC7E0F398FA0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5F230A2C-E15E-41D9-8781-4AF5CA3E381E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8F4C5D67-B302-4D5E-86D3-E308EE0C607E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D2F70BCB-D9EC-44EA-93E7-C33A22842BF2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0569E8E5-928F-4D8D-93AE-056F350503EF"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:190DDFDA-8456-4B27-972C-5E815FA29EBD"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EB66F52A-826A-4B19-9DAB-4F305456531E"/>
    <permissions:permissions rdf:nodeID="N683cfcc1a998490e9f4e66a577f55456"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:B4ADFA01-70C2-42CC-87CC-869B81E3104E"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:37727E88-1331-4D52-A885-1D4C9745A521</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:1B6D964C-5C7B-4A8B-91D1-71E48BED6297"/>
    <pav:createdOn>2014-07-13 12:46:12 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:DE4A37C3-330E-406A-8B07-E596729011D4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4019A76A-1D16-4F04-8CBF-FF855DD2A7A2">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:07:17 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:636BB7C2-294D-452D-967D-461DEF7A510A"/>
    <pav:lineageUri>urn:domeoserver:annotation:09B51181-CF5C-416F-839B-FE6DF66105EA</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BB046B1-5949-4043-9525-70D01EC3816C">
    <ao:exact>risperidone</ao:exact>
    <ao:suffix> is bound to albumin and α1-acid glycoprotein. The plasma protein binding of risperidone is 90%, and that of its major metabolite, 9-hydroxyrisperidone, is 77%. Neither risperidone nor 9-hydroxyrisperidone displaces each other from plasma binding sites. </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9BB046B1-5949-4043-9525-70D01EC3816C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> is rapidly distributed. The volume of distribution is 1 to 2 L/kg. In plasma, </ao:prefix>
    <pav:createdOn>2014-07-13 11:10:51 -0400</pav:createdOn>
    <domeo:uuid>9BB046B1-5949-4043-9525-70D01EC3816C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0B2918C2-A28D-40C3-8147-F19D09B7119C">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-07 09:37:58 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A3612760-5AFD-415B-8269-F1483D859C5D"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:90F5AA7B-F35E-4B00-A666-C6FE8F1B0324">
    <pav:createdOn>2014-07-13 11:10:35 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:86034B03-551B-406A-BFE8-B44A1CB16857</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:FADFAA32-BB4A-4542-AEFD-2B7D80177234"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A22D7450-FC77-45A4-B835-3948870AD344">
    <pav:createdOn>2014-07-13 12:34:35 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A22D7450-FC77-45A4-B835-3948870AD344"/>
    <ao:exact>Sertraline</ao:exact>
    <domeo:uuid>A22D7450-FC77-45A4-B835-3948870AD344</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> hydrochloride is supplied for oral administration as scored tablets containing sertraline hydrochloride equivalent to 25, 50, 100, 150 and 200 mg of sertraline and the following inactive ingredients: dibasic calcium phosphate dihydrate, hydroxypropyl ce</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-20.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AA9BE1F2-854A-4E7D-8C64-DCE1158C5D96">
    <ao:exact>N</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:suffix>-</ao:suffix>
    <pav:createdOn>2014-07-07 09:58:57 -0400</pav:createdOn>
    <ao:prefix>Injection is predicted to provide a pharmacological effect of sildenafil and its </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AA9BE1F2-854A-4E7D-8C64-DCE1158C5D96"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N683cfcc1a998490e9f4e66a577f55456">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315">
    <ao:item rdf:resource="urn:domeoclient:uuid:DA8337B7-4497-4F34-93E8-291B9ED278CB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:72594949-CA92-4CEF-8CB6-0072661759A0"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:6BF180C6-926E-4F67-84B0-1DC9E664C663"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:7EA46EFB-1A94-409D-B432-24203EA5400F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3CE3E7D7-79CE-4BA9-8CA0-7B7A05D77AFC"/>
    <pav:createdOn>2014-07-13 12:35:54 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:5E38DB7B-2B38-491B-8686-9C2D434ACD79"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:167FB68A-5943-4F0E-8CC6-C6BAB7625E4F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:76D2A20E-E18E-4676-958D-12D182D20430"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C7A86B1F-FEF9-4500-AC47-4A4949A51ABD"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:B9174469-54E0-4FAB-8165-210C50F1F809"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C0B517A8-DCD4-4740-A77D-8490A77113AE"/>
    <pav:lastSavedOn>2014-07-13 12:41:09 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3BEBBBC1-7503-4FA0-9B16-ED708F2AE108"/>
    <permissions:permissions rdf:nodeID="N9645bb12c6664e0a859bf486d2521a23"/>
    <pav:lineageUri>urn:domeoserver:annotationset:7698170F-5CE1-49C4-9F55-5ED355B5BEA7</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:4EEAF739-3D04-465D-8AC0-35EAE4B00AE0"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:12FA04F1-54A6-4C48-9FDA-8E372C8A648A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:190DDFDA-8456-4B27-972C-5E815FA29EBD">
    <pav:createdOn>2014-07-13 12:47:19 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5039F6DC-F654-4E38-8762-0E1BD92F058C"/>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nf99da3c207b0419c8325728d0058b71e"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:6778C161-ADEE-4D2A-83DD-90876C90F77A</pav:lineageUri>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B4ADFA01-70C2-42CC-87CC-869B81E3104E">
    <ao:context rdf:resource="urn:domeoclient:uuid:6A0AE7AB-260B-4296-BC83-DB443FEE5161"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-13 12:46:24 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:56FD27A9-9A20-480B-9750-E65B79E50EDB</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C15235C1-3B10-4949-B8E4-1D7FCCD3AC4B">
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:1230CFBE-6F41-4107-8D50-5F5A730D40C5"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 11:07:49 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:89484DAB-0EA9-4ACB-BC2F-9FEC34383940</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B98C3482-C44D-4C61-ACC3-D277890BCE91">
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-07 11:23:25 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:exact>REVATIO </ao:exact>
    <ao:suffix>Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B98C3482-C44D-4C61-ACC3-D277890BCE91"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9C5564E-F653-404D-B333-299E63141AF5">
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:228452B8-64FE-4746-AB80-952A986140F5</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-13 11:15:52 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:D78CEABF-EE24-4AFF-81A9-B148050EFE16"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1BF82CCC-CD60-4AB5-8C1B-4176DC1A85F3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:16:53 -0400</pav:createdOn>
    <ao:suffix> was 3 hours (CV=30%) in extensive metabolizers and 20 hours (CV=40%) in poor metabolizers. The apparent half-life of 9-hydroxyrisperidone was about 21 hours (CV=20%) in extensive metabolizers and 30 hours (CV=25%) in poor metabolizers. The pharmacokinet</ao:suffix>
    <ao:prefix>The apparent half-life of </ao:prefix>
    <domeo:uuid>1BF82CCC-CD60-4AB5-8C1B-4176DC1A85F3</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1BF82CCC-CD60-4AB5-8C1B-4176DC1A85F3"/>
    <ao:exact>risperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F46BEE2C-B82E-4386-96D7-C74221898C04">
    <pav:lineageUri>urn:domeoserver:annotation:90D2913F-1AFA-432E-968A-2D879173B288</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:2B951EF5-B48C-4B58-B273-480990730DEA"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-13 11:15:12 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5FBE9544-4653-482C-B065-70CA3AA07309">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>5FBE9544-4653-482C-B065-70CA3AA07309</domeo:uuid>
    <ao:exact>rifampin</ao:exact>
    <ao:prefix>, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5FBE9544-4653-482C-B065-70CA3AA07309"/>
    <ao:suffix>, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other drugs meta</ao:suffix>
    <pav:createdOn>2014-07-13 11:15:53 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3612760-5AFD-415B-8269-F1483D859C5D">
    <ao:prefix>iastolic blood pressure of 8/5 mmHg). The decrease in blood pressure was most notable approximately 1–2 hours after dosing, and was not different from placebo at 8 hours. Similar effects on blood pressure were noted with 25 mg, 50 mg and 100 mg doses of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:suffix>, therefore the effects are not related to dose or plasma levels within this dosage range. Larger effects were recorded among patients receiving concomitant nitrates [see Contraindications (4)].</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A3612760-5AFD-415B-8269-F1483D859C5D"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>sildenafil</ao:exact>
    <pav:createdOn>2014-07-07 09:37:58 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:70919722-5B5F-4E86-A52F-8A64A1EFDA72">
    <pav:lineageUri>urn:domeoserver:annotation:34E978B5-2DD2-44FE-B1ED-248C51C20EC2</pav:lineageUri>
    <pav:createdOn>2014-07-13 12:56:11 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:C1C706B9-7F27-4C22-8F0D-E46B96B35A86"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B4E5EBBF-965D-41F8-B54E-0CF48653C43C">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:76B68D47-1D9C-4B2A-B9A6-CFE359C93E64"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:56:09 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:F61FAB34-A2B1-45CE-B6A6-123A03AAD69D</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E728D92E-FEA6-4EE6-9E40-E59051DEB8E3">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:DDCD9620-FC48-419B-ACE3-537915C7889C</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-13 11:09:21 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:043FCC7B-7CBD-4BE5-9962-3F6CF2B132DB"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D3F1A48F-9525-4CA3-8022-C7885849CBC2">
    <domeo:belongsToSet>urn:domeoclient:uuid:6A05795B-B1AB-4DB3-A12F-2765CBCC2FED</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:0EB4AE1F-6DB3-497B-AAE0-DD8E03C51D30</pav:lineageUri>
    <pav:createdOn>2014-07-13 12:34:41 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 12:34:42 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:4FCA7E7B-CC82-4455-94C0-73C09ED070C1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6EC654F2-7C5C-4C0B-9973-518245983B18">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-13 11:16:01 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:2B0A8F16-94F6-4911-8E78-98C4225AC672</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:36129C88-CE12-4AF2-ABDA-B2DC6006FD29"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:89155DC0-3493-4590-8DD7-44717F141C27">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:09:15 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:94085E4A-F1A0-40E6-8805-C846AF27EEDD</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:0A1E742B-4ABE-40BF-84E5-2A5F57F232F2"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D83441D-0916-4D83-A136-CA26588E67D0">
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:prefix> and </ao:prefix>
    <domeo:uuid>0D83441D-0916-4D83-A136-CA26588E67D0</domeo:uuid>
    <ao:suffix> combined, after single and multiple doses, are similar in extensive and poor metabolizers.</ao:suffix>
    <pav:createdOn>2014-07-13 11:13:49 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0D83441D-0916-4D83-A136-CA26588E67D0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC416A29-1315-42C5-90FA-652412A6AD12">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdOn>2014-07-07 09:40:48 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:8EA1563F-47E7-4983-918E-643A5D2021DC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1E597BBC-9857-4D08-953B-5CBE831F5884">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:DE221D8D-564A-4ED6-8FA2-FEACF6BADD9F</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:26:45 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:body rdf:nodeID="Nf74e64afe6d446b49cb63347d5d462f0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:B7CF0599-4EF7-4EA9-AA71-F3F0B7596EF6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9F3CA373-B79A-4B2D-8C96-BFB67CB4B175">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:6784E1B8-4746-4B76-AE23-2ACB7CBA8ADF</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 11:16:05 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:612855C1-32AF-48C7-A341-A649DD897808"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1E6C968E-32AF-45A2-96F3-10B3A640C99F">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1E6C968E-32AF-45A2-96F3-10B3A640C99F"/>
    <ao:suffix> could be subject to two kinds of drug-drug interactions. First, inhibitors of CYP 2D6 interfere with conversion of risperidone to 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. This occurs with quinidine, giving essentially all recipients a risperidone</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>Risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>1E6C968E-32AF-45A2-96F3-10B3A640C99F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:13:53 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76D2A20E-E18E-4676-958D-12D182D20430">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 12:37:40 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:B2317F54-7476-4D82-9C44-76D503E6DA71</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:575F0CD0-2CEC-4594-9019-B1A6C8BA5D55"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2D04CBBE-379A-4D9F-BDD4-AA3663CD4669">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>2D04CBBE-379A-4D9F-BDD4-AA3663CD4669</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2D04CBBE-379A-4D9F-BDD4-AA3663CD4669"/>
    <ao:exact>Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers</ao:exact>
    <pav:createdOn>2014-07-07 11:36:13 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EAE26632-A8D8-4E80-ADE1-8902853460F6">
    <ao:prefix>After chronic dosing of 80 mg </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>TID </ao:exact>
    <pav:createdOn>2014-07-07 09:39:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EAE26632-A8D8-4E80-ADE1-8902853460F6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC8C2FEA-C8BE-4A4F-98E3-3E4C44B65C83">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> to 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. This occurs with quinidine, giving essentially all recipients a risperidone pharmacokinetic profile typical of poor metabolizers. The therapeutic benefits and adverse effects of risperidone in patients </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:14:00 -0400</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CC8C2FEA-C8BE-4A4F-98E3-3E4C44B65C83"/>
    <domeo:uuid>CC8C2FEA-C8BE-4A4F-98E3-3E4C44B65C83</domeo:uuid>
    <ao:prefix> could be subject to two kinds of drug-drug interactions. First, inhibitors of CYP 2D6 interfere with conversion of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:098AA784-6695-4935-9450-C87D502EDBCD">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>erythromycin</ao:exact>
    <ao:suffix>, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>was co-administered with </ao:prefix>
    <pav:createdOn>2014-07-07 11:23:07 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:098AA784-6695-4935-9450-C87D502EDBCD"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B6E9A08-C112-4656-8901-F8802CD64317">
    <pav:createdOn>2014-07-13 12:45:35 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A</domeo:belongsToSet>
    <ao:body rdf:nodeID="Ne98fefd482bf4efaa1ebf4ad1bb5ff2b"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:2BF9F224-82C0-470E-9645-8A6965E66A04"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:B0DBD770-879A-4A78-90BD-890A235DEC8D</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7CC41192-004E-44F9-8E3D-0FF7CECF1DC2">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:2E085178-1D00-47D7-8B18-1A094C6C93A7</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:F3F94F7A-3299-4ECD-8A0C-54D9B0E17A6D"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:13:30 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F63AE259-E4D8-48C8-9143-FADBBFAD548B">
    <pav:createdOn>2014-07-13 11:07:54 -0400</pav:createdOn>
    <ao:exact>serotonin</ao:exact>
    <ao:prefix> has low to moderate affinity (Ki of 47 to 253 nM) for the </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F63AE259-E4D8-48C8-9143-FADBBFAD548B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> 5HT1C, 5HT1D, and 5HT1A receptors, weak affinity (Ki of 620 to 800 nM) for the dopamine D1 and haloperidol-sensitive sigma site, and no affinity (when tested at concentrations &gt;10-5 M) for cholinergic muscarinic or β1 and β2 adrenergic receptors.</ao:suffix>
    <domeo:uuid>F63AE259-E4D8-48C8-9143-FADBBFAD548B</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2CE66065-C68D-4E90-911C-F8B5E04B3813">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <ao:exact>norethindrone</ao:exact>
    <ao:suffix>. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 12:37:33 -0400</pav:createdOn>
    <domeo:uuid>2CE66065-C68D-4E90-911C-F8B5E04B3813</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2CE66065-C68D-4E90-911C-F8B5E04B3813"/>
    <ao:prefix> and </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C6FF426-D0F6-4DFE-8C13-8BD0EAA98C6F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 12:46:15 -0400</pav:createdOn>
    <ao:suffix> 400 mg to six healthy male volunteers. After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14</ao:suffix>
    <ao:prefix> 100 mg was administered as a single oral dose alone and two hours after a single dose of </ao:prefix>
    <ao:exact>cimetidine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0C6FF426-D0F6-4DFE-8C13-8BD0EAA98C6F"/>
    <domeo:uuid>0C6FF426-D0F6-4DFE-8C13-8BD0EAA98C6F</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56F428F6-CAF7-4343-B57C-103B1BA935EB">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 11:10:06 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:679C48F0-BCFA-4F3B-93B6-03B171A529E1</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:532294F2-A52D-4732-85C4-0F955156A615"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A46A827E-4936-4BBC-8078-913DD6DAA84E">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 11:14:00 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:CC8C2FEA-C8BE-4A4F-98E3-3E4C44B65C83"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:5B70F474-288C-4C1B-AF18-E0EF9B5EE27B</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1836E85-2D43-46EF-848C-F6204E5A50A7">
    <pav:lineageUri>urn:domeoserver:annotation:67C91220-39BA-4E36-AF83-B063DCBE7679</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-13 12:56:03 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:42DD4654-83AE-4111-86D8-574617EB3CAB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED359A65-2894-4EE7-9430-453B2C8C6D26">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>. </ao:prefix>
    <domeo:uuid>ED359A65-2894-4EE7-9430-453B2C8C6D26</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ED359A65-2894-4EE7-9430-453B2C8C6D26"/>
    <pav:createdOn>2014-07-13 12:40:24 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2CF891F7-2E96-4382-8EDB-5C061E8E1AFA">
    <pav:createdOn>2014-07-07 09:42:06 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:8F1DD8EF-72E2-425B-B98B-233F1591A13F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:575F0CD0-2CEC-4594-9019-B1A6C8BA5D55">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>fluconazole</ao:exact>
    <ao:suffix> dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to </ao:suffix>
    <pav:createdOn>2014-07-13 12:37:40 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:575F0CD0-2CEC-4594-9019-B1A6C8BA5D55"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>575F0CD0-2CEC-4594-9019-B1A6C8BA5D55</domeo:uuid>
    <ao:prefix>. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CAC294B3-5790-4488-B65C-CB3269F765C6">
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-13 11:16:30 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:366925ED-C6A8-41CA-97EB-602399B8DB72"/>
    <pav:lineageUri>urn:domeoserver:annotation:E7F026CF-6162-4445-A7F9-6B029DDC6F96</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EBDA4EF3-E793-47E4-9F6F-74592DE48307">
    <ao:prefix>. The mean increase in </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 12:44:29 -0400</pav:createdOn>
    <domeo:uuid>EBDA4EF3-E793-47E4-9F6F-74592DE48307</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EBDA4EF3-E793-47E4-9F6F-74592DE48307"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>ethinyl estradiol</ao:exact>
    <ao:suffix> AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%).</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7950DCED-7411-4B59-B629-CB1341A53897">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7950DCED-7411-4B59-B629-CB1341A53897"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-07 09:51:17 -0400</pav:createdOn>
    <ao:suffix>on Blood Pressure</ao:suffix>
    <ao:exact>REVATIO </ao:exact>
    <ao:prefix>Effects of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8EA1563F-47E7-4983-918E-643A5D2021DC">
    <pav:createdOn>2014-07-07 09:40:48 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>on Vision</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Effects of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8EA1563F-47E7-4983-918E-643A5D2021DC"/>
    <ao:exact>REVATIO </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:518CD4C6-1719-48AB-B300-84A10DEACB68">
    <ao:context rdf:resource="urn:domeoclient:uuid:35CE9A7F-F23D-4EBE-B09F-02A153717FBA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-13 11:10:38 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:01596A5C-8D3C-4B38-BEFB-CD0AFC09802B</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:02D92735-6D44-4DFA-A2E9-75A5A3D4DCF9">
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:DC34C3D8-C58F-483B-80DB-B65FEBB2EC20"/>
    <pav:createdOn>2014-07-07 09:42:51 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C2EEFE36-AE7E-4BF4-943E-03D2760C673E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C2EEFE36-AE7E-4BF4-943E-03D2760C673E"/>
    <pav:createdOn>2014-07-13 11:08:45 -0400</pav:createdOn>
    <ao:prefix>The clinical effect from </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>risperidone</ao:exact>
    <domeo:uuid>C2EEFE36-AE7E-4BF4-943E-03D2760C673E</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> results from the combined concentrations of risperidone and its major metabolite, 9-hydroxyrisperidone [see 12 CLINICAL PHARMACOLOGY]. Antagonism at receptors other than D2 and 5HT2 [see 12 CLINICAL PHARMACOLOGY] may explain some of the other effects of</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BB4AA59B-BD34-4506-A617-157D639949C4">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-13 12:44:29 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:EBDA4EF3-E793-47E4-9F6F-74592DE48307"/>
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:12FF752F-ABCD-4F14-B2B9-41A0476FEF33</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6FD9D48D-F639-4F09-ABA6-F4B259681453">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-07 09:59:10 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:BCAC0F86-EF1B-48A6-B71C-46750D478032</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:50649F2A-1F77-4AC3-AA05-9C465AAF3D79"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:489FB94C-2475-4EC7-BE20-CF92749745A7">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:B0AC894E-27E2-43D9-BFEB-167E8117247A"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:6A05795B-B1AB-4DB3-A12F-2765CBCC2FED</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:88C1F1C9-E75C-4A69-9BFF-84FAF6F2C2ED</pav:lineageUri>
    <pav:createdOn>2014-07-13 12:34:38 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-13 12:34:42 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/CE1B6F16-57BD-40EB-AB83-B1A40576F8C0">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>rifampin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ABB70710-CA87-4445-8EB3-1BFDDC4636FE">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ABB70710-CA87-4445-8EB3-1BFDDC4636FE"/>
    <ao:suffix> doses should be reduced in patients with renal disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS].</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>ABB70710-CA87-4445-8EB3-1BFDDC4636FE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> and its active metabolite decreased by 60% compared to young healthy subjects. </ao:prefix>
    <pav:createdOn>2014-07-13 11:17:32 -0400</pav:createdOn>
    <ao:exact>Risperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:539264FC-F626-408A-BB71-03BC387083CB">
    <pav:createdOn>2014-07-13 11:18:02 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:88B8196E-4906-4695-9420-CEEF74F91F98</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:AB311B8D-11CB-4B44-BDC1-9641D482BE0D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76258D2D-1630-4254-82ED-C3434163EAE3">
    <ao:suffix> in patients receiving quinidine have not been evaluated, but observations in a modest number (N≅70) of poor metabolizers given risperidone do not suggest important differences between poor and extensive metabolizers. Second, co-administration of known e</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:15:09 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:76258D2D-1630-4254-82ED-C3434163EAE3"/>
    <ao:prefix> pharmacokinetic profile typical of poor metabolizers. The therapeutic benefits and adverse effects of </ao:prefix>
    <domeo:uuid>76258D2D-1630-4254-82ED-C3434163EAE3</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5039F6DC-F654-4E38-8762-0E1BD92F058C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5039F6DC-F654-4E38-8762-0E1BD92F058C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <ao:suffix> However, the administration of</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>5039F6DC-F654-4E38-8762-0E1BD92F058C</domeo:uuid>
    <ao:prefix> 400 mg to six healthy male volunteers. </ao:prefix>
    <pav:createdOn>2014-07-13 12:47:19 -0400</pav:createdOn>
    <ao:exact>After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F4C5D67-B302-4D5E-86D3-E308EE0C607E">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:B06BD29E-2481-4EA0-885B-420749EBE703"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:46:20 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:044837BF-E4FA-4C9D-8EA0-E23B27E2EC72</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D3737933-330F-487F-B41C-CDB0FF5C6F1C">
    <ao:exact>metabolite </ao:exact>
    <pav:createdOn>2014-07-07 09:58:59 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>equivalent to that of a 20 mg oral dose.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D3737933-330F-487F-B41C-CDB0FF5C6F1C"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:612855C1-32AF-48C7-A341-A649DD897808">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:612855C1-32AF-48C7-A341-A649DD897808"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:suffix> [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other drugs metabolized by CYP 2D6. Relatively weak binding of risperidone to the enzyme suggests this is unlikely [see 7 DRUG INTERACTIONS].</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:16:05 -0400</pav:createdOn>
    <domeo:uuid>612855C1-32AF-48C7-A341-A649DD897808</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0AC105E-C659-4D3F-9F13-4104BCC29CDE">
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:13:36 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:65044E3B-BE66-455E-B576-1B8DF996B6B4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:6A3A3F06-7277-4FF9-9E27-EBB7510D87E7</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BB359BC3-6C0F-427E-B961-0838B54690D5">
    <pav:createdOn>2014-07-07 09:38:27 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:exact>sildenafil </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG. After chronic dosing of 80 mg TID to patients with pulmonary arterial hypertension, no clinically relevant effects on ECG were reported.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BB359BC3-6C0F-427E-B961-0838B54690D5"/>
    <ao:prefix>Single oral doses of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:01E43715-3610-4176-8FB9-E2D7C94F6C63">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:181381FE-800A-4970-81D8-2B14B7735770"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B294F73B-169E-4106-90EF-3C87099953E8">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>The clinical effect from risperidone results from the combined concentrations of risperidone and its major metabolite, 9-hydroxyrisperidone [see 12 CLINICAL PHARMACOLOGY].</ao:exact>
    <ao:suffix> Antagonism at receptors other than D2 and 5HT2 [see 12 CLINICAL PHARMACOLOGY] may explain some of the other effects of risperidone</ao:suffix>
    <domeo:uuid>B294F73B-169E-4106-90EF-3C87099953E8</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B294F73B-169E-4106-90EF-3C87099953E8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:29:18 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9011E52E-6FAE-42BF-913B-D3EF952E8A2B">
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:B9422143-55C7-4DC9-89FD-1C96FFB68383</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:04:07 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F3D2A83E-9B62-495D-A7E7-A17FEF5E2561"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B7BF8E5-F410-48B2-AF56-5421E6B7FF0B">
    <domeo:uuid>5B7BF8E5-F410-48B2-AF56-5421E6B7FF0B</domeo:uuid>
    <ao:suffix>, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolis</ao:suffix>
    <pav:createdOn>2014-07-13 11:15:50 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5B7BF8E5-F410-48B2-AF56-5421E6B7FF0B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> do not suggest important differences between poor and extensive metabolizers. Second, co-administration of known enzyme inducers (e.g., </ao:prefix>
    <ao:exact>carbamazepine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42423629-C409-4AD4-BBE6-7C86A696F03E">
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-07 09:41:41 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:6791DC23-BC40-4E62-815B-0DA5CCA7BD4F"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A151EB77-7400-49F2-9673-BFAD2171D5CD">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:17F49268-30E8-4066-B9B1-4521C34B09E9</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:A3654752-C204-49F0-B3F7-87C2EE277992"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-13 11:07:24 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4CEC1749-9AA0-4FDA-B649-6B3CDED4298A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4CEC1749-9AA0-4FDA-B649-6B3CDED4298A"/>
    <ao:exact>fluconazole</ao:exact>
    <ao:prefix> AUC and a significant increase in apparent oral clearance of </ao:prefix>
    <domeo:uuid>4CEC1749-9AA0-4FDA-B649-6B3CDED4298A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours. (See PRECAUTI</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 12:56:07 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:65044E3B-BE66-455E-B576-1B8DF996B6B4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:65044E3B-BE66-455E-B576-1B8DF996B6B4"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:13:36 -0400</pav:createdOn>
    <ao:prefix>, whereas poor CYP 2D6 metabolizers convert it much more slowly. Although extensive metabolizers have lower </ao:prefix>
    <ao:suffix> and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, are similar in extensive and poor metabolizers.</ao:suffix>
    <ao:exact>risperidone</ao:exact>
    <domeo:uuid>65044E3B-BE66-455E-B576-1B8DF996B6B4</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:57E98049-37B0-4F70-963B-F0D12C3B36C7">
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 11:22:43 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:996E26F9-829E-4D62-867F-4975211CECA5</pav:lineageUri>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:EFE95BF7-1349-414E-B68F-6C5149A03072"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF873305-5222-4D37-9C71-925D3C390B7A">
    <ao:suffix>, and </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:09:51 -0400</pav:createdOn>
    <ao:prefix>, its major metabolite, 9-</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>CF873305-5222-4D37-9C71-925D3C390B7A</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CF873305-5222-4D37-9C71-925D3C390B7A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72843AE3-90CC-43FD-BCEC-E83B4E3A7EDF">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:10:19 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:77F990A5-C7A6-4873-A32F-AD9607EFDE51"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:7D999E14-4D2E-4EE2-945B-2011BD864F5E</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A05795B-B1AB-4DB3-A12F-2765CBCC2FED">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:92530361-A562-40CE-942A-CC181EBE7AD7"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:lineageUri>urn:domeoserver:annotationset:428337F8-4C91-47BA-A4E8-ABD1A86D1498</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D3F1A48F-9525-4CA3-8022-C7885849CBC2"/>
    <permissions:permissions rdf:nodeID="N9f211c81ec6a4639b9f04a0c4176de45"/>
    <pav:createdOn>2014-07-13 12:34:35 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-20.txt.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:489FB94C-2475-4EC7-BE20-CF92749745A7"/>
    <pav:lastSavedOn>2014-07-13 12:34:42 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:222C9B55-A770-41C7-AF04-566E7C7A1DBC">
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-07 09:43:42 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B9D56D7C-5C37-4BCA-B9C4-0605E9E54998"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ABF527C0-D635-49E4-BC45-911EBB72D2E8">
    <pav:createdOn>2014-07-13 11:10:47 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ABF527C0-D635-49E4-BC45-911EBB72D2E8"/>
    <domeo:uuid>ABF527C0-D635-49E4-BC45-911EBB72D2E8</domeo:uuid>
    <ao:prefix>Distribution: </ao:prefix>
    <ao:suffix> is rapidly distributed. The volume of distribution is 1 to 2 L/kg. In plasma, risperidone is bound to albumin and α1-acid glycoprotein. The plasma protein binding of risperidone is 90%, and that of its major metabolite, 9-hydroxyrisperidone, is 77%. Nei</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B49DFB13-7D38-41A6-989C-F0F22BFBCA7D">
    <pav:createdOn>2014-07-13 11:15:18 -0400</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <ao:suffix> do not suggest important differences between poor and extensive metabolizers. Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma c</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <domeo:uuid>B49DFB13-7D38-41A6-989C-F0F22BFBCA7D</domeo:uuid>
    <ao:prefix> have not been evaluated, but observations in a modest number (N≅70) of poor metabolizers given </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B49DFB13-7D38-41A6-989C-F0F22BFBCA7D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8232EB8B-B7ED-4583-BE33-F0AD71DA4D1C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-07 09:36:49 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina and involved in the phototransduction pathway of the retina. This lower selectivity is thought to be the basis for abnormalities related to color vision observed wit</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8232EB8B-B7ED-4583-BE33-F0AD71DA4D1C"/>
    <ao:prefix>terases (10-fold for PDE6, &gt; 80-fold for PDE1, &gt; 700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11). The approximately 4,000-fold selectivity for PDE5 versus PDE3 is important because PDE3 is involved in control of cardiac contractility. </ao:prefix>
    <ao:exact>Sildenafil </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D318A30A-F708-43F6-AB5B-A9D659E063BF">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/ED3BCC98-B0FE-4421-B54B-7B2414CF4328"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/851B37FE-C029-42CD-9AFE-2CD0906FA393"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:371BCC12-3242-4854-9882-2DB2B2EE1A70">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:371BCC12-3242-4854-9882-2DB2B2EE1A70"/>
    <ao:prefix> AUC of any individual subject in this study compared to placebo dosing. The individual AUC values of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <ao:exact>norethindrone</ao:exact>
    <domeo:uuid>371BCC12-3242-4854-9882-2DB2B2EE1A70</domeo:uuid>
    <ao:suffix> decreased very slightly (&lt;5%) in 3 of the 21 subjects after fluconazole treatment.</ao:suffix>
    <pav:createdOn>2014-07-13 12:38:53 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B7CF0599-4EF7-4EA9-AA71-F3F0B7596EF6">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The mechanism of action of risperidone, as with other drugs used to treat schizophrenia, is unknown. However, it has been proposed that the drug’s therapeutic activity in schizophrenia is mediated through a combination of dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>B7CF0599-4EF7-4EA9-AA71-F3F0B7596EF6</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B7CF0599-4EF7-4EA9-AA71-F3F0B7596EF6"/>
    <pav:createdOn>2014-07-13 11:26:44 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AEC296E5-554D-42F1-BF6A-CA09B038958F">
    <domeo:uuid></domeo:uuid>
    <ao:exact>sildenafil </ao:exact>
    <ao:suffix>to healthy volunteers, the largest mean change from baseline in supine systolic and supine diastolic blood pressures was a decrease of 9.0 mmHg and 8.4 mmHg, respectively.</ao:suffix>
    <ao:prefix>After chronic dosing of 80 mg TID </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AEC296E5-554D-42F1-BF6A-CA09B038958F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-07 09:39:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FE717566-90D0-4B59-B00F-B053CAE639C4">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-13 11:13:49 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:D7AEA2C8-0FF3-482D-BC96-255927C0D5D8</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:0D83441D-0916-4D83-A136-CA26588E67D0"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2537CEFB-4053-4AC9-8731-C65B1AC5D0F9">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:15:55 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D526C276-CAAE-4E9B-8038-08BB2FB8FBBD"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:F1E65BAF-B906-4702-93F2-2AB99EAC8EC2</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB66F52A-826A-4B19-9DAB-4F305456531E">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:46:18 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:40519342-F06B-41D2-A39A-795BA218AF7B"/>
    <pav:lineageUri>urn:domeoserver:annotation:A5C90995-9DDD-408E-A19C-6AA024D77686</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:135F1FE6-83FC-4E58-95A7-4C08AED291BA">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:135F1FE6-83FC-4E58-95A7-4C08AED291BA"/>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>135F1FE6-83FC-4E58-95A7-4C08AED291BA</domeo:uuid>
    <ao:suffix> in subjects with liver disease were comparable to those in young healthy subjects, the mean free fraction of risperidone in plasma was increased by about 35% because of the diminished concentration of both albumin and α1-acid glycoprotein. Risperidone d</ao:suffix>
    <ao:prefix>Hepatic Impairment: While the pharmacokinetics of </ao:prefix>
    <pav:createdOn>2014-07-13 11:17:38 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7E8BEB68-80C9-4767-BEC0-5810B8C956C0">
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:prefix>Injection is predicted to provide a pharmacological effect of sildenafil and its N-</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>desmethyl </ao:exact>
    <ao:suffix>metabolite equivalent to that of a 20 mg oral dose.</ao:suffix>
    <pav:createdOn>2014-07-07 09:58:55 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7E8BEB68-80C9-4767-BEC0-5810B8C956C0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3C4287B-36A9-48BF-8081-A39BEF5F3C51">
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-07 09:38:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:BB359BC3-6C0F-427E-B961-0838B54690D5"/>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:00CDF4D6-2271-4B2A-9836-98BD00E7E952">
    <ao:suffix> or </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> 50 mg once daily for 10 days in 10 healthy women. There was no significant difference in </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:00CDF4D6-2271-4B2A-9836-98BD00E7E952"/>
    <ao:exact>ethinyl estradiol</ao:exact>
    <pav:createdOn>2014-07-13 12:42:05 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <domeo:uuid>00CDF4D6-2271-4B2A-9836-98BD00E7E952</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DD06894B-6765-494F-98ED-9B2C217D26FD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> rapidly into 9-hydroxyrisperidone, whereas poor CYP 2D6 metabolizers convert it much more slowly. Although extensive metabolizers have lower risperidone and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of rispe</ao:suffix>
    <domeo:uuid>DD06894B-6765-494F-98ED-9B2C217D26FD</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:13:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DD06894B-6765-494F-98ED-9B2C217D26FD"/>
    <ao:prefix>m (about 6% to 8% of Caucasians, and a very low percentage of Asians, have little or no activity and are “poor metabolizers”) and to inhibition by a variety of substrates and some non-substrates, notably quinidine. Extensive CYP 2D6 metabolizers convert </ao:prefix>
    <ao:exact>risperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7D37CC60-618E-46B6-8C99-BA7D598E3762">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-07 11:23:40 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:DDCCCF49-E95D-4DE0-8F83-128C04E4F1DB</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:ECF8E578-9A91-41E0-91AC-502E097E5A11"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:114406CD-55D0-459D-A4F0-CEDB09E201C6">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7CBD8092-1453-4994-9F29-22622E743A15"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94239CD6-2883-459B-A125-FF55B9791833">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:4B9E6D9B-AF88-4692-9DEF-8B6FA5D8F2B7</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:D909BDC5-468E-434E-B3E5-632F1565E73C"/>
    <pav:createdOn>2014-07-13 11:11:25 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BD9047F-C1DA-4B64-92B7-4D031972C9CF">
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-07 09:39:24 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:AEC296E5-554D-42F1-BF6A-CA09B038958F"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F049BA4A-8DAF-49C1-ABA1-6E76A2F6DA6B">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/1FCFC8E7-95A0-4188-9582-891391C2CFE6"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/A36E11B0-6726-4AD1-ACC7-4E8E59A350EB"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC34C3D8-C58F-483B-80DB-B65FEBB2EC20">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DC34C3D8-C58F-483B-80DB-B65FEBB2EC20"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>is cleared predominantly by the CYP3A (major route) and cytochrome P450 2C9 (CYP2C9, minor route) hepatic microsomal isoenzymes. The major circulating metabolite results from N-desmethylation of sildenafil, and is, itself, further metabolized. This metab</ao:suffix>
    <pav:createdOn>2014-07-07 09:42:51 -0400</pav:createdOn>
    <ao:exact>Sildenafil </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C4061A3-979D-486B-9CDA-1CFF771CCB5B">
    <pav:lineageUri>urn:domeoserver:annotation:67C400B9-D19B-4746-9FE2-12A58EE79507</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:10:47 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:ABF527C0-D635-49E4-BC45-911EBB72D2E8"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0DDFAFFA-5DE6-4D3B-BC30-6421E6531AD8">
    <ao:exact>levonorgestrel</ao:exact>
    <pav:createdOn>2014-07-13 12:41:59 -0400</pav:createdOn>
    <ao:suffix> AUC after the administration of 50 mg of fluconazole. The mean increase in ethinyl estradiol AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%).</ao:suffix>
    <ao:prefix>Oral contraceptives were administered as a single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women. There was no significant difference in ethinyl estradiol or </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0DDFAFFA-5DE6-4D3B-BC30-6421E6531AD8"/>
    <domeo:uuid>0DDFAFFA-5DE6-4D3B-BC30-6421E6531AD8</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA428F64-D782-46F5-B866-2FBC24D3F4F8">
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:9F3CAE5F-12DF-463B-A0AD-4F223784EC31</pav:lineageUri>
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-07 09:58:58 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:EA1C9791-9797-4F15-A767-767B900E9B87"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F353BFC5-D6B5-4819-8EA8-0A44F2223E3B">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F353BFC5-D6B5-4819-8EA8-0A44F2223E3B"/>
    <pav:createdOn>2014-07-07 09:37:19 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>sildenafil </ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>may be the basis for the enhanced platelet anti-aggregatory activity of nitric oxide observed in vitro, and the mild peripheral arterial-venous dilatation in vivo.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:prefix>In addition to pulmonary vascular smooth muscle and the corpus cavernosum, PDE5 is also found in other tissues including vascular and visceral smooth muscle and in platelets. The inhibition of PDE5 in these tissues by </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F4851EA8-C391-4F16-B8F8-81A3F2688015">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluconazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:92436D94-1FB4-49B2-B20D-385CA961A940">
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:1E6C968E-32AF-45A2-96F3-10B3A640C99F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-13 11:13:53 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:19D86C58-A255-44F5-87D8-8E8795312D29</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:167FB68A-5943-4F0E-8CC6-C6BAB7625E4F">
    <pav:lineageUri>urn:domeoserver:annotation:A6AB8619-AAFD-4D65-8839-376407154A96</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-13 12:38:47 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:F5A4FF79-C22B-475D-8775-B7CA929DA67C"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76A2A466-4D5D-4AA1-8114-FAD1FF0E6FC0">
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:76A2A466-4D5D-4AA1-8114-FAD1FF0E6FC0"/>
    <ao:suffix>Cmax and a 210% increase in sildenafil AUC.</ao:suffix>
    <pav:createdOn>2014-07-07 11:24:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>(100 mg single dose) resulted in a 140% increase in </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:exact>sildenafil </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC9FB0B5-1564-4BF2-A4E4-4D05B0A1AB86">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 09:37:19 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:F353BFC5-D6B5-4819-8EA8-0A44F2223E3B"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CAB91F57-2F70-4DDB-9BF8-A50167C8BBCE">
    <ao:exact>In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 12:40:40 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>CAB91F57-2F70-4DDB-9BF8-A50167C8BBCE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CAB91F57-2F70-4DDB-9BF8-A50167C8BBCE"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1C706B9-7F27-4C22-8F0D-E46B96B35A86">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C1C706B9-7F27-4C22-8F0D-E46B96B35A86"/>
    <pav:createdOn>2014-07-13 12:56:11 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>fluconazole</ao:exact>
    <ao:suffix> increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours. (See PRECAUTIONS.)</ao:suffix>
    <domeo:uuid>C1C706B9-7F27-4C22-8F0D-E46B96B35A86</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <ao:prefix> AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F94384BA-7A08-4E0D-A89C-A73959BAA203">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:55C36B4E-CDCE-4B16-94D5-178014A48A7F"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:09:28 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:2D596385-5BFD-4D31-8E3A-AF1CD1B646BB</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DFB0D433-995A-4EB5-B9CC-EAE5A0C16DEA">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> plus 9-hydroxyrisperidone.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>. Consequently, the clinical effect of the drug results from the combined concentrations of </ao:prefix>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:12:29 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DFB0D433-995A-4EB5-B9CC-EAE5A0C16DEA"/>
    <domeo:uuid>DFB0D433-995A-4EB5-B9CC-EAE5A0C16DEA</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1A7382E8-45D1-4872-98EA-20455089A06B">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1A7382E8-45D1-4872-98EA-20455089A06B"/>
    <ao:suffix>, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.</ao:suffix>
    <ao:prefix>In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor </ao:prefix>
    <pav:createdOn>2014-07-07 11:23:45 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>saquinavir</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EEC761C8-1050-4E1A-A450-D460F8514160">
    <pav:createdOn>2014-07-13 11:18:21 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:FE75629E-FE6A-4361-BE28-79148B042D27</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:984E4D2D-A998-4068-9BF7-F709348DD1B2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E72D7D03-AAE5-42A5-A83A-3C68C2C2BCB6">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/C9B2FC03-3B32-472D-B469-B9F86400F4C6"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/5A962BFF-E73B-4290-B642-C49A7EBCD1B8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DE5C582E-1F4C-478C-9DDC-DAB4C0C1ABFF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:FFE74587-6133-48F1-B1FA-716CCC2AA2F3</pav:lineageUri>
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-07 09:58:57 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:AA9BE1F2-854A-4E7D-8C64-DCE1158C5D96"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72584FCC-E5F1-4130-993B-ED469AE3E810">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:15:50 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:4F012046-527A-4412-B5FE-F766182124E4</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:5B7BF8E5-F410-48B2-AF56-5421E6B7FF0B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B4D9B85-636E-45EE-9796-1A7AE7E45DCF">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1B4D9B85-636E-45EE-9796-1A7AE7E45DCF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance.</ao:suffix>
    <ao:exact>risperidone</ao:exact>
    <pav:createdOn>2014-07-13 11:11:43 -0400</pav:createdOn>
    <domeo:uuid>1B4D9B85-636E-45EE-9796-1A7AE7E45DCF</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix> (10 mcg/mL) caused only a slight increase in the free fraction of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0E54D90-28C4-48FD-B72C-21011511DD58">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:CC36BBDD-6E14-44E8-9E21-FE419782FE72</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:body rdf:nodeID="N56cdd45116ba42378521833b6c383a2e"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 12:45:51 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:58C4B9F6-E8BB-4567-9FF2-3D87C6E9284C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7E52164F-6FEF-4A1A-A55B-01314BCEB19B">
    <domeo:uuid>7E52164F-6FEF-4A1A-A55B-01314BCEB19B</domeo:uuid>
    <ao:suffix>. Consequently, the clinical effect of the drug results from the combined concentrations of risperidone plus 9-hydroxyrisperidone.</ao:suffix>
    <pav:createdOn>2014-07-13 11:12:23 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7E52164F-6FEF-4A1A-A55B-01314BCEB19B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix>, has similar pharmacological activity as </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DBBBE91C-3E2F-469A-9254-58328E372FEA">
    <pav:createdOn>2014-07-07 09:37:41 -0400</pav:createdOn>
    <ao:suffix>100 mg administered to healthy volunteers produced decreases in supine blood pressure (mean maximum decrease in systolic/diastolic blood pressure of 8/5 mmHg). The decrease in blood pressure was most notable approximately 1–2 hours after dosing, and was </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>sildenafil </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DBBBE91C-3E2F-469A-9254-58328E372FEA"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:prefix>Single oral doses of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C8D05CE4-8287-449A-8921-AFACBAEE2002">
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 09:39:32 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:52192391-30EB-46A9-93CB-47EC77CE40BC"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4E77E45D-0BB8-4168-8CAF-9D1591E37A36">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:11:50 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:A1D65D6C-6A4B-478F-8140-AA87C27DB44D</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:A29DA787-54E3-4422-B166-2BA6676BC91D"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C84DD53D-5B64-47C5-92EE-E2D0E78BD754">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> is extensively metabolized in the liver. The main metabolic pathway is through hydroxylation of risperidone to 9-hydroxyrisperidone by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, 9-hydroxyrisperidone, h</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C84DD53D-5B64-47C5-92EE-E2D0E78BD754"/>
    <pav:createdOn>2014-07-13 11:11:55 -0400</pav:createdOn>
    <ao:prefix>Metabolism and Drug Interactions: </ao:prefix>
    <domeo:uuid>C84DD53D-5B64-47C5-92EE-E2D0E78BD754</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C0B517A8-DCD4-4740-A77D-8490A77113AE">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 12:40:40 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N962525f6f4b447b9ae5ef01bad49d655"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:CAB91F57-2F70-4DDB-9BF8-A50167C8BBCE"/>
    <pav:lineageUri>urn:domeoserver:annotation:8D387F71-D7EF-42BB-8B40-0EBCAFF64A75</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E0ECD29D-DAB1-4D63-85F1-1839E3B04BF6">
    <ao:prefix> nor </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>E0ECD29D-DAB1-4D63-85F1-1839E3B04BF6</domeo:uuid>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <pav:createdOn>2014-07-13 11:11:19 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E0ECD29D-DAB1-4D63-85F1-1839E3B04BF6"/>
    <ao:suffix> displaces each other from plasma binding sites. High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydro</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:17E64297-0A57-4C9B-94C4-18ED1956FCF7">
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-07 09:51:17 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:2F1405B4-F41E-4809-AC54-DA4B296E83DB</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:7950DCED-7411-4B59-B629-CB1341A53897"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0025BED1-B4CA-4D8F-9C43-B2F10841CCF4">
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:F6864EB3-C97B-4F46-976B-E976F8C03348"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-13 11:15:56 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:0A047BE5-CEF6-494B-A811-C7F89C6D2A1B</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/C9B2FC03-3B32-472D-B469-B9F86400F4C6">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>risperidone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E7907DD5-4FA4-4B5A-99D9-9D24B76931C6">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:4A784235-A949-4FFD-9438-52955B529B7A</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:1D92FA7B-3CB7-4C89-9E21-9980B649BC2E"/>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-07 11:22:37 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3FEE8D2-9817-490A-AF14-CC53E5ADFBF2">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F3FEE8D2-9817-490A-AF14-CC53E5ADFBF2"/>
    <ao:exact>fluconazole</ao:exact>
    <ao:prefix>A third study evaluated the potential interaction of once weekly dosing of </ao:prefix>
    <domeo:uuid>F3FEE8D2-9817-490A-AF14-CC53E5ADFBF2</domeo:uuid>
    <pav:createdOn>2014-07-13 12:35:54 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <ao:suffix> 300 mg to 21 normal females taking an oral contraceptive containing ethinyl estradiol and norethindrone. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, flucona</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BDA75ADA-742A-402B-AE97-4438F99C61FC">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 09:36:02 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:3EBDA2ED-165F-4B57-B4BE-CFA63CD5C5A6"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:32B1CD5D-3CD7-4D5E-BD76-57F6F0A9480A">
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-07 09:34:12 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5672F5D0-071A-4DE9-9A98-BD20431A00C2"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:12FA04F1-54A6-4C48-9FDA-8E372C8A648A">
    <pav:lineageUri>urn:domeoserver:annotation:13CBA444-A83A-48E8-AC3C-79379FB9E6F7</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:A810EBBA-9C6C-4A0D-9FD2-AFA2874096F5"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-13 12:38:23 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68010F53-B903-4110-B73F-5CE843CA2E18">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-07 09:42:08 -0400</pav:createdOn>
    <ao:prefix>is 105 L, indicating distribution into the tissues. </ao:prefix>
    <ao:suffix>and its major circulating N-desmethyl metabolite are both approximately 96% bound to plasma proteins. Protein binding is independent of total drug concentrations.</ao:suffix>
    <ao:exact>Sildenafil </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:68010F53-B903-4110-B73F-5CE843CA2E18"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AF657FF8-3529-4A9B-9294-13C604834E0A">
    <ao:context rdf:resource="urn:domeoclient:uuid:211F5FD6-FC29-4AC5-96E1-14E088108ABB"/>
    <pav:lineageUri>urn:domeoserver:annotation:AB1C3D00-CC4C-4CA3-B347-69BA6BFE0FBF</pav:lineageUri>
    <ao:body rdf:nodeID="Nda74ddd69b384cc3bb0e9e283e5dbc9f"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:56:54 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D860A1B6-8D5E-4FE4-9EDB-4E1397B29BBD">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>sildenafil</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/136411</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2EC3D9EC-E1A7-4DD1-A006-50B08564335E">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:01F5BBDB-E20A-4996-9E0A-81199182C6B7</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:E17F3ACA-8486-4702-886B-6FA2562FDEFF"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:44:35 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3CE3E7D7-79CE-4BA9-8CA0-7B7A05D77AFC">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:746D73EB-609F-4ABC-8FAC-F496DCDBACDA</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:5C901133-925A-4BA8-947F-0FE9FB6D60DB"/>
    <pav:createdOn>2014-07-13 12:38:04 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <permissions:permissions rdf:nodeID="N8c1ff42287b3489e92d2de3fed3fb66d"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:lineageUri>urn:domeoserver:annotationset:66EBA4F6-77AF-4AB4-A3E8-E0D406200FF6</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:962DC691-3D08-4224-8D22-C0DD8D9F24CA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B4E5EBBF-965D-41F8-B54E-0CF48653C43C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:11E26B74-9DE2-4B10-A8C9-A250D2747B3E"/>
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A5A1F4E1-991C-4D93-AC6A-4DEDDF392601"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:70919722-5B5F-4E86-A52F-8A64A1EFDA72"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 12:55:59 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:35685454-E730-4B12-A923-46EE9655234C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C1836E85-2D43-46EF-848C-F6204E5A50A7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AF657FF8-3529-4A9B-9294-13C604834E0A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2AC08E4-8A5F-4E68-B2F1-20AFB690BAC7">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E2AC08E4-8A5F-4E68-B2F1-20AFB690BAC7"/>
    <ao:suffix>exposure without concomitant medication is shown to be 5-fold higher at a dose of 80 mg TID compared to its exposure at a dose of 20 mg TID. This concentration range covers the same increased sildenafil exposure observed in specifically-designed drug int</ao:suffix>
    <pav:createdOn>2014-07-07 11:22:40 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:exact>Sildenafil </ao:exact>
    <ao:prefix>clearance when it was co-administered with CYP3A inhibitors. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8C5BA635-EF8B-4165-A2A6-5832D61A15BF">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:lastSavedOn>2014-07-07 11:35:31 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:7AACEF8D-2EBC-4F0B-94B2-190650E562F6</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdOn>2014-07-07 11:35:30 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5F97F910-5C88-42D5-BF36-6EFC8C9A3DD1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:body rdf:nodeID="Nd2d9ecce81a44c7db8a676dec92c7e46"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:007F6835-1CAF-4F0B-8BFD-311D8BFD8926">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-07 11:23:01 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:007F6835-1CAF-4F0B-8BFD-311D8BFD8926"/>
    <ao:prefix>When a single 100 mg dose of </ao:prefix>
    <ao:exact>sildenafil </ao:exact>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/093D1F2A-587E-4B3C-AAF4-10347561D8A9">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/136411</dailymed:activeMoietyRxCUI>
    <rdfs:label>sildenafil</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/964F2661-87EF-4D00-87C8-D1C5E12C0ECB">
    <rdfs:label>fluconazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55E92945-9B4A-406D-8BFF-54471B2E432E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> was about 21 hours (CV=20%) in extensive metabolizers and 30 hours (CV=25%) in poor metabolizers. The pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, were similar in extensive and poor metabolizers, wi</ao:suffix>
    <ao:prefix> was 3 hours (CV=30%) in extensive metabolizers and 20 hours (CV=40%) in poor metabolizers. The apparent half-life of </ao:prefix>
    <pav:createdOn>2014-07-13 11:17:02 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:55E92945-9B4A-406D-8BFF-54471B2E432E"/>
    <domeo:uuid>55E92945-9B4A-406D-8BFF-54471B2E432E</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5D480921-AA61-499B-9C3F-3043269104B4">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-07 09:40:13 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:CFAD9029-E218-4465-9975-0A69DA967891"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C7A86B1F-FEF9-4500-AC47-4A4949A51ABD">
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 12:38:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:47D86654-5774-44C8-91EF-5162D998152D</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:A54DB360-9E9B-4E55-AC79-A80E321825D3"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F6864EB3-C97B-4F46-976B-E976F8C03348">
    <pav:createdOn>2014-07-13 11:15:56 -0400</pav:createdOn>
    <ao:suffix> may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other drugs metabolized by CYP 2D6. Relatively weak b</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>F6864EB3-C97B-4F46-976B-E976F8C03348</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F6864EB3-C97B-4F46-976B-E976F8C03348"/>
    <ao:exact>risperidone</ao:exact>
    <ao:prefix>) with </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42DD4654-83AE-4111-86D8-574617EB3CAB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>42DD4654-83AE-4111-86D8-574617EB3CAB</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:42DD4654-83AE-4111-86D8-574617EB3CAB"/>
    <ao:exact>fluconazole</ao:exact>
    <pav:createdOn>2014-07-13 12:56:03 -0400</pav:createdOn>
    <ao:prefix> administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in </ao:prefix>
    <ao:suffix> AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole hal</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6791DC23-BC40-4E62-815B-0DA5CCA7BD4F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (25–63%). Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. When </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>is taken with a high-fat meal, the rate of absorption is reduced, with a mean delay in Tmax of 60 minutes and a mean reduction in Cmax of 29%. The mean steady state volume of distribution (Vss) for sildenafil is 105 L, indicating distribution into the ti</ao:suffix>
    <pav:createdOn>2014-07-07 09:41:41 -0400</pav:createdOn>
    <ao:exact>REVATIO </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6791DC23-BC40-4E62-815B-0DA5CCA7BD4F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D346F3FB-2896-495E-BF67-B2BC6E8F5714">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (25–63%). Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. When REVATIO is taken</ao:suffix>
    <ao:exact>REVATIO </ao:exact>
    <pav:createdOn>2014-07-07 09:41:30 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D346F3FB-2896-495E-BF67-B2BC6E8F5714"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3967C16-EC04-423B-908A-CF2BC1EC4011">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>serotonin</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:04:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> Type 2 (D2) and </ao:prefix>
    <domeo:uuid>F3967C16-EC04-423B-908A-CF2BC1EC4011</domeo:uuid>
    <ao:suffix> Type 2 (5HT2) receptor antagonism.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F3967C16-EC04-423B-908A-CF2BC1EC4011"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5F230A2C-E15E-41D9-8781-4AF5CA3E381E">
    <pav:createdOn>2014-07-13 12:46:27 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:C0DCB0F4-61CC-48CE-8688-567F2327B321"/>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:6DC77E85-D03E-4E33-9B0F-4B8826F63FA7</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4441B5B-C18F-4F66-90A8-3A3306CD1C90">
    <ao:exact>desmethyl </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C4441B5B-C18F-4F66-90A8-3A3306CD1C90"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:suffix>metabolite are both approximately 96% bound to plasma proteins. Protein binding is independent of total drug concentrations.</ao:suffix>
    <ao:prefix>and its major circulating N-</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-07 09:42:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E76B5D64-7248-4EBD-A023-3820BFDEFD26">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C0F812BF-119E-4BE1-AAA3-BF2DAE39B76F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-07 09:36:31 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71CADA90-E1E5-4B50-9394-FDFC0B1512B0">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-4.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:390CA5FE-7939-4F69-B612-7F5C21A06481"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:02:33 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:BA49274C-11BD-499C-B6F3-8E9B55B40E77</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdOn>2014-07-13 11:02:05 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="N65fa39a768be45569cc90c27aaec1f83"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E766D1AC-45BC-4579-89AD-BE0DEC69FC35">
    <ao:suffix>-</ao:suffix>
    <ao:prefix>and its major circulating </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-07 09:42:25 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E766D1AC-45BC-4579-89AD-BE0DEC69FC35"/>
    <ao:exact>N</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0569E8E5-928F-4D8D-93AE-056F350503EF">
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:0C6FF426-D0F6-4DFE-8C13-8BD0EAA98C6F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-13 12:46:15 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:FC7F51C8-D140-4695-B609-DCDA64270F6D</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:697C8F03-1543-4427-9D85-7967FCEA3100">
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-07 09:41:30 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:D346F3FB-2896-495E-BF67-B2BC6E8F5714"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/7C1B3FD3-CA8D-4D2F-B094-F0DB74BF2108">
    <rdfs:label>ethinyl estradiol</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4124</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:366925ED-C6A8-41CA-97EB-602399B8DB72">
    <ao:suffix> and its metabolites are eliminated via the urine and, to a much lesser extent, via the feces. As illustrated by a mass balance study of a single 1 mg oral dose of 14C-risperidone administered as solution to three healthy male volunteers, total recovery </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:16:30 -0400</pav:createdOn>
    <ao:prefix>Excretion: </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Risperidone</ao:exact>
    <domeo:uuid>366925ED-C6A8-41CA-97EB-602399B8DB72</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:366925ED-C6A8-41CA-97EB-602399B8DB72"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E8680340-7715-4656-A160-A6F608AD7CE9">
    <pav:createdOn>2014-07-13 11:08:54 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F31EE1EC-A22F-4FE9-8763-7C623AD7B0BE"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:9F72602C-A51D-443A-8FED-EF0310ADB89F</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71E5047C-5690-4D45-9A6E-FB1384C14928">
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4A268B82-4B69-4D00-A6E9-95F225012877"/>
    <pav:createdOn>2014-07-13 11:16:15 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:DFC21707-69A6-4E64-9438-1D6C69F0352F</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:92DB5361-BE2B-4C69-B141-FB431E8EFC22">
    <pav:createdOn>2014-07-13 11:17:24 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:BF0C3C69-52C2-4462-9A48-708B80A1A097</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:0991F050-6152-45E8-8D40-DC901E368C9E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A1E742B-4ABE-40BF-84E5-2A5F57F232F2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:09:15 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <domeo:uuid>0A1E742B-4ABE-40BF-84E5-2A5F57F232F2</domeo:uuid>
    <ao:suffix> is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0A1E742B-4ABE-40BF-84E5-2A5F57F232F2"/>
    <ao:prefix> is well absorbed. The absolute oral bioavailability of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3ED57AC4-296D-4C8D-9873-49C193F69BBA">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:CE972F8D-C1AD-46A9-B34B-1D883FDAF1EC"/>
    <pav:createdOn>2014-07-07 09:40:14 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A54DB360-9E9B-4E55-AC79-A80E321825D3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compared to placebo dosi</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 12:38:35 -0400</pav:createdOn>
    <ao:prefix> and </ao:prefix>
    <domeo:uuid>A54DB360-9E9B-4E55-AC79-A80E321825D3</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A54DB360-9E9B-4E55-AC79-A80E321825D3"/>
    <ao:exact>norethindrone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:36129C88-CE12-4AF2-ABDA-B2DC6006FD29">
    <domeo:uuid>36129C88-CE12-4AF2-ABDA-B2DC6006FD29</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:16:01 -0400</pav:createdOn>
    <ao:suffix> and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other drugs metabolized by CYP 2D6. Relatively weak binding of risperidone to the enzyme suggests this is unlikely [see 7 DRUG </ao:suffix>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> may cause a decrease in the combined plasma concentrations of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:36129C88-CE12-4AF2-ABDA-B2DC6006FD29"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CA230F0A-406C-43AE-88DE-A7FD67CF4D61">
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 11:12:34 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:814003AB-50EC-489D-967C-53D890293957</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:EEA0DB9F-24A6-4283-B426-FDECA24BE603"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23E5F3F5-E089-460E-A736-58E2FC44ADC6">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:C84DD53D-5B64-47C5-92EE-E2D0E78BD754"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:8FDCFCF8-1579-4EA3-B0D9-73159007B108</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 11:11:55 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B3435A02-DBAF-4D33-9A80-3B78037721AE">
    <ao:suffix> acts as an antagonist at other receptors, but with lower potency. Risperidone has low to moderate affinity (Ki of 47 to 253 nM) for the serotonin 5HT1C, 5HT1D, and 5HT1A receptors, weak affinity (Ki of 620 to 800 nM) for the dopamine D1 and haloperidol-</ao:suffix>
    <ao:prefix> Type 2 (D2), α1 and α2 adrenergic, and H1 histaminergic receptors. </ao:prefix>
    <domeo:uuid>B3435A02-DBAF-4D33-9A80-3B78037721AE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Risperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B3435A02-DBAF-4D33-9A80-3B78037721AE"/>
    <pav:createdOn>2014-07-13 11:07:46 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1085914C-2530-49EB-92B4-1E4BC17AEBAC">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1085914C-2530-49EB-92B4-1E4BC17AEBAC"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-4.txt.html</ao:hasSource>
    <domeo:uuid>1085914C-2530-49EB-92B4-1E4BC17AEBAC</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> is 400 mg daily given as 200 mg b.i.d. Dosage should be increased gradually until an optimal clinical response is obtained, generally at 600 to 1200 mg per day. If treatment is to be discontinued, the dosage should be reduced gradually over a period of </ao:suffix>
    <ao:exact>acebutolol</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>The usual initial dosage of </ao:prefix>
    <pav:createdOn>2014-07-13 11:02:05 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52192391-30EB-46A9-93CB-47EC77CE40BC">
    <pav:createdOn>2014-07-07 09:39:32 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:52192391-30EB-46A9-93CB-47EC77CE40BC"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>TID </ao:exact>
    <ao:prefix>After chronic dosing of 80 mg </ao:prefix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA4C8A6E-17D4-47F8-A369-67AF061E9037">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-07 09:44:07 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A412DBFC-2FE0-43FA-A538-B84D822A5BFD"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:636BB7C2-294D-452D-967D-461DEF7A510A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> is a selective monoaminergic antagonist with high affinity (Ki of 0.12 to 7.3 nM) for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), α1 and α2 adrenergic, and H1 histaminergic receptors. Risperidone acts as an antagonist at other receptors, but with</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:07:17 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:636BB7C2-294D-452D-967D-461DEF7A510A"/>
    <ao:exact>Risperidone</ao:exact>
    <domeo:uuid>636BB7C2-294D-452D-967D-461DEF7A510A</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A810EBBA-9C6C-4A0D-9FD2-AFA2874096F5">
    <ao:exact>norethindrone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A810EBBA-9C6C-4A0D-9FD2-AFA2874096F5"/>
    <ao:suffix> compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cause a decrease in t</ao:suffix>
    <pav:createdOn>2014-07-13 12:38:23 -0400</pav:createdOn>
    <ao:prefix> and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>A810EBBA-9C6C-4A0D-9FD2-AFA2874096F5</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B088F7FA-8870-4336-965B-4A558E3F08B0">
    <ao:context rdf:resource="urn:domeoclient:uuid:ABB70710-CA87-4445-8EB3-1BFDDC4636FE"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:0D1F3FB5-E327-4ED5-A129-940CBC83C151</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:17:32 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:11E26B74-9DE2-4B10-A8C9-A250D2747B3E">
    <pav:lineageUri>urn:domeoserver:annotation:74A8BD59-3770-4E00-8C04-C4D9A82E8F47</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:EBCFB082-4C3F-4C27-B1B4-7DE7E01178ED"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:55:59 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FC76D7A1-BCF3-4AF0-92CC-E5D2F09F6BD7">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7FE9AC63-C53E-4EF9-AEF0-CC1F82EDA7C3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:30903A1B-437C-4ABA-B24D-6148F07F178D">
    <ao:prefix>, its major metabolite, 9-hydroxyrisperidone, and </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:30903A1B-437C-4ABA-B24D-6148F07F178D"/>
    <pav:createdOn>2014-07-13 11:09:35 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <domeo:uuid>30903A1B-437C-4ABA-B24D-6148F07F178D</domeo:uuid>
    <ao:exact>risperidone</ao:exact>
    <ao:suffix> plus 9-hydroxyrisperidone are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily). Following oral administration of solution or tablet, mean peak plasma concentrations of risperidone occurred at about 1 hour. Peak conce</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E38DB7B-2B38-491B-8686-9C2D434ACD79">
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:ED359A65-2894-4EE7-9430-453B2C8C6D26"/>
    <ao:body rdf:nodeID="N05b636d8cede42a9979895e21bc8a8af"/>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 12:40:24 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:B018D6F2-5667-4118-9A44-AD32984915AA</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DA8337B7-4497-4F34-93E8-291B9ED278CB">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:37:44 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:6D41F524-FA45-4B72-94A7-36317513638D</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:8214D15C-5AF1-47D0-A63C-30543353403D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EA1C9791-9797-4F15-A767-767B900E9B87">
    <ao:exact>-</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EA1C9791-9797-4F15-A767-767B900E9B87"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-07 09:58:58 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9D56D7C-5C37-4BCA-B9C4-0605E9E54998">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-07 09:43:42 -0400</pav:createdOn>
    <ao:suffix>, and is, itself, further metabolized. This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% of the parent drug. In healthy volunteers, plasma concentrations of this metabolit</ao:suffix>
    <ao:exact>sildenafil</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B9D56D7C-5C37-4BCA-B9C4-0605E9E54998"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:125C14DB-1F35-4667-846F-F789D6D0AFCF">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E72D7D03-AAE5-42A5-A83A-3C68C2C2BCB6"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3805F006-2423-4B51-87AB-CAE85C6B4E21">
    <pav:createdOn>2014-07-13 11:10:15 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A95EA236-59E2-47FB-878A-81116D82930F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:4E13C50F-B8D6-4676-A219-AD5C04FF7CDB</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5F97F910-5C88-42D5-BF36-6EFC8C9A3DD1">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5F97F910-5C88-42D5-BF36-6EFC8C9A3DD1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-07 11:35:30 -0400</pav:createdOn>
    <domeo:uuid>5F97F910-5C88-42D5-BF36-6EFC8C9A3DD1</domeo:uuid>
    <ao:exact>When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC)</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CFAD9029-E218-4465-9975-0A69DA967891">
    <ao:exact>TID </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>After chronic dosing of 80 mg </ao:prefix>
    <pav:createdOn>2014-07-07 09:40:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>sildenafil to patients with systemic hypertension, the mean change from baseline in systolic and diastolic blood pressures was a decrease of 9.4 mmHg and 9.1 mmHg, respectively.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CFAD9029-E218-4465-9975-0A69DA967891"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DE4A37C3-330E-406A-8B07-E596729011D4">
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:8631DCC5-B27D-47B4-B621-CA41E8FF2E7A</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:ECB23C3B-E835-480F-B541-EB5CBBAB2855"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 12:46:33 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A6F0B480-ABD4-436B-8A6F-A4BD34827F73">
    <pav:createdOn>2014-07-13 11:11:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:945BD1E4-DE7D-4DBC-804B-A4E048F20780</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:30818391-5098-4A86-BF01-5AB0C0597335"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/BAE41BF7-CAA3-4865-832D-24EB9699E14C">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4053</dailymed:activeMoietyRxCUI>
    <rdfs:label>erythromycin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B18CF78-48CD-4D32-B4F4-88F8072C8185">
    <pav:createdOn>2014-07-13 11:11:19 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:A50036CB-D487-48AB-9CE3-45B6CA3540CD</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:E0ECD29D-DAB1-4D63-85F1-1839E3B04BF6"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E13140FE-59B4-45B2-A524-CAED051C4F9D">
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:68010F53-B903-4110-B73F-5CE843CA2E18"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-07 09:42:08 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:78BBB6BD-543C-42F3-B5F5-431ADE5F4D72">
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>78BBB6BD-543C-42F3-B5F5-431ADE5F4D72</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix> to </ao:prefix>
    <pav:createdOn>2014-07-13 11:12:09 -0400</pav:createdOn>
    <ao:suffix> by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, 9-hydroxyrisperidone, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug results from the combined concentr</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:78BBB6BD-543C-42F3-B5F5-431ADE5F4D72"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E5DE379E-8BB3-4609-BFC6-A0E275978ADC">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-07 11:23:45 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:C1698FA2-C1AE-4B3D-9950-C56ECC1CFB3C</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:1A7382E8-45D1-4872-98EA-20455089A06B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:77F990A5-C7A6-4873-A32F-AD9607EFDE51">
    <ao:prefix> occurred at about 1 hour. Peak concentrations of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:suffix> occurred at about 3 hours in extensive metabolizers, and 17 hours in poor metabolizers. Steady-state concentrations of risperidone are reached in 1 day in extensive metabolizers and would be expected to reach steady-state in about 5 days in poor metabol</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <domeo:uuid>77F990A5-C7A6-4873-A32F-AD9607EFDE51</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:77F990A5-C7A6-4873-A32F-AD9607EFDE51"/>
    <pav:createdOn>2014-07-13 11:10:19 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:651C0626-4BF6-4B96-A66A-7385C6456D51">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:DD06894B-6765-494F-98ED-9B2C217D26FD"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:298F93DA-79DF-482C-B367-9A29F14FB3D6</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:13:26 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8ABD9FDA-0F08-474A-A9C8-437A5346F2AC">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 09:40:23 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:20B4F69C-E14E-46A0-8FCE-6AAC4D5EF0B0"/>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3654752-C204-49F0-B3F7-87C2EE277992">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A3654752-C204-49F0-B3F7-87C2EE277992"/>
    <ao:prefix> is a selective monoaminergic antagonist with high affinity (Ki of 0.12 to 7.3 nM) for the </ao:prefix>
    <ao:suffix> Type 2 (5HT2), dopamine Type 2 (D2), α1 and α2 adrenergic, and H1 histaminergic receptors. Risperidone acts as an antagonist at other receptors, but with lower potency. Risperidone has low to moderate affinity (Ki of 47 to 253 nM) for the serotonin 5HT1</ao:suffix>
    <ao:exact>serotonin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:07:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>A3654752-C204-49F0-B3F7-87C2EE277992</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D526C276-CAAE-4E9B-8038-08BB2FB8FBBD">
    <domeo:uuid>D526C276-CAAE-4E9B-8038-08BB2FB8FBBD</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D526C276-CAAE-4E9B-8038-08BB2FB8FBBD"/>
    <ao:suffix>) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other drugs metabolized by CYP 2D6.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>phenobarbital</ao:exact>
    <pav:createdOn>2014-07-13 11:15:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, and </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A">
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:010AF63D-C71E-4A93-9F41-8E5764F068ED"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:A0645479-B3CA-4505-B451-B003C3B19554"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:1B6E9A08-C112-4656-8901-F8802CD64317"/>
    <domeo:deleted>false</domeo:deleted>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5A5707CC-D3AC-4807-9E98-6536CDC7AC55"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:67CFE2D6-F2AA-4465-A433-B26BEA64FB5E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BB4AA59B-BD34-4506-A617-157D639949C4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:CE4C4228-2925-4DF5-84E2-5A5B519C5595</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N9b55efd2c5c74419aa56dbb74fb7cb53"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F0E54D90-28C4-48FD-B72C-21011511DD58"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2EC3D9EC-E1A7-4DD1-A006-50B08564335E"/>
    <pav:createdOn>2014-07-13 12:41:59 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:70B9E8E9-06ED-4420-9CDE-4E0F36F57CC9">
    <ao:suffix> combined, after single and multiple doses, were similar in extensive and poor metabolizers, with an overall mean elimination half-life of about 20 hours.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:17:15 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:70B9E8E9-06ED-4420-9CDE-4E0F36F57CC9"/>
    <ao:prefix> and </ao:prefix>
    <domeo:uuid>70B9E8E9-06ED-4420-9CDE-4E0F36F57CC9</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1D92FA7B-3CB7-4C89-9E21-9980B649BC2E">
    <ao:prefix>Population data from patients in clinical trials indicated a reduction in </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-07 11:22:37 -0400</pav:createdOn>
    <ao:exact>sildenafil </ao:exact>
    <ao:suffix>clearance when it was co-administered with CYP3A inhibitors. Sildenafil exposure without concomitant medication is shown to be 5-fold higher at a dose of 80 mg TID compared to its exposure at a dose of 20 mg TID. This concentration range covers the same </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1D92FA7B-3CB7-4C89-9E21-9980B649BC2E"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/04F5EE18-51BD-4A42-A9E7-52826EE0EA8B">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>saquinavir</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/83395</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35CE9A7F-F23D-4EBE-B09F-02A153717FBA">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:35CE9A7F-F23D-4EBE-B09F-02A153717FBA"/>
    <ao:suffix> can be given with or without meals.</ao:suffix>
    <domeo:uuid>35CE9A7F-F23D-4EBE-B09F-02A153717FBA</domeo:uuid>
    <ao:prefix>. Thus, </ao:prefix>
    <pav:createdOn>2014-07-13 11:10:38 -0400</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E202AAE6-7DCA-486D-9C29-8CB3B82CFECF">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:30903A1B-437C-4ABA-B24D-6148F07F178D"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-13 11:09:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:70E60126-522D-4A50-BCBB-D49738745AFC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/B7CB635F-4EBF-434B-9159-71DC46A33588">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4124</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>ethinyl estradiol</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2F70BCB-D9EC-44EA-93E7-C33A22842BF2">
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:F4CD88A4-5CEC-433F-9DFF-C429C94CCEA2</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:46:37 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:57242808-9748-4ED3-908E-E0054E0C8BBE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CBE541BF-AED9-48E5-ACA0-9309C45B20F5">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-13 11:12:09 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:133A11F3-97FE-4A36-97AB-CF474CA6CAA0</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:78BBB6BD-543C-42F3-B5F5-431ADE5F4D72"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N194479db07e844a3abef316ba99c1dab">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08713DDF-0935-4B63-B281-AEE56A8D7628">
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:A6C1D994-FD1E-4778-8CFC-8AF61A3DA42E</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:6BF6E19B-3833-4401-A589-B16E9522C485"/>
    <pav:createdOn>2014-07-07 09:58:53 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9AF0B949-C133-4703-9F65-362D4B5B4494">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 11:11:10 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:C0DB2807-8137-4A89-A166-930A58544F71</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:6887274E-F614-42FD-904F-B7E202949297"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EEA0DB9F-24A6-4283-B426-FDECA24BE603">
    <pav:createdOn>2014-07-13 11:12:34 -0400</pav:createdOn>
    <ao:prefix> plus </ao:prefix>
    <ao:suffix>.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EEA0DB9F-24A6-4283-B426-FDECA24BE603"/>
    <domeo:uuid>EEA0DB9F-24A6-4283-B426-FDECA24BE603</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D17A3686-1703-468A-9054-837449C245F1">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>cimetidine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9174469-54E0-4FAB-8165-210C50F1F809">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:2CE66065-C68D-4E90-911C-F8B5E04B3813"/>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:2051B080-40BC-4A2C-B53F-A08613EB9C84</pav:lineageUri>
    <pav:createdOn>2014-07-13 12:37:33 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:67CFE2D6-F2AA-4465-A433-B26BEA64FB5E">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:42:01 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:C5023B49-22AF-4880-9F9A-B1FCB16EAE71"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:2B2D2409-EC63-45B4-9720-BB70CEBD3CE2</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16FE2F0D-3BF4-4708-9147-BD5159B47059">
    <ao:prefix>r drugs. CYP 2D6 is subject to genetic polymorphism (about 6% to 8% of Caucasians, and a very low percentage of Asians, have little or no activity and are “poor metabolizers”) and to inhibition by a variety of substrates and some non-substrates, notably </ao:prefix>
    <ao:suffix>. Extensive CYP 2D6 metabolizers convert </ao:suffix>
    <domeo:uuid>16FE2F0D-3BF4-4708-9147-BD5159B47059</domeo:uuid>
    <ao:exact>quinidine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:16FE2F0D-3BF4-4708-9147-BD5159B47059"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:14:31 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA2C0A64-143A-46D5-A408-01FC3EC62525">
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:5F4EA581-2F5C-4FF1-8DA3-D5101E760F69"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:A65B00D7-6AC0-4BC7-B831-3E6D23520F80</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:28:14 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:20B4F69C-E14E-46A0-8FCE-6AAC4D5EF0B0">
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-07 09:40:23 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>After chronic dosing of 80 mg </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>TID </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:20B4F69C-E14E-46A0-8FCE-6AAC4D5EF0B0"/>
    <ao:suffix>sildenafil to patients with pulmonary arterial hypertension, lesser reductions than above in systolic and diastolic blood pressures were observed (a decrease in both of 2 mmHg).</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/5AC4FDB3-99BB-4CC2-9A03-87893DB04756">
    <rdfs:label>cimetidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B5E75366-F0BF-442F-852E-19C5EDDC84EE">
    <ao:context rdf:resource="urn:domeoclient:uuid:C4441B5B-C18F-4F66-90A8-3A3306CD1C90"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-07 09:42:24 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6BF180C6-926E-4F67-84B0-1DC9E664C663">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:B86B4616-9A36-459A-BD9A-3E75A70DBB8E</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 12:38:39 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:E2C79BAB-965C-479E-824A-F2884B348419"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F63A36F-F819-4E40-9C8A-C518B5519787">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7F63A36F-F819-4E40-9C8A-C518B5519787"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> in plasma was increased by about 35% because of the diminished concentration of both </ao:prefix>
    <domeo:uuid>7F63A36F-F819-4E40-9C8A-C518B5519787</domeo:uuid>
    <ao:exact>albumin</ao:exact>
    <ao:suffix> and α1-acid glycoprotein. Risperidone doses should be reduced in patients with liver disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS].</ao:suffix>
    <pav:createdOn>2014-07-13 11:17:56 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FADFAA32-BB4A-4542-AEFD-2B7D80177234">
    <ao:prefix>Food Effect: Food does not affect either the rate or extent of absorption of </ao:prefix>
    <pav:createdOn>2014-07-13 11:10:35 -0400</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FADFAA32-BB4A-4542-AEFD-2B7D80177234"/>
    <ao:suffix>. Thus, risperidone can be given with or without meals.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>FADFAA32-BB4A-4542-AEFD-2B7D80177234</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C446162-FA92-4715-9095-A116DC12F4C8">
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:22154A78-8E19-4B3A-8326-6AAAB8A19F14</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B49DFB13-7D38-41A6-989C-F0F22BFBCA7D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-13 11:15:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5C901133-925A-4BA8-947F-0FE9FB6D60DB">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5C901133-925A-4BA8-947F-0FE9FB6D60DB"/>
    <domeo:uuid>5C901133-925A-4BA8-947F-0FE9FB6D60DB</domeo:uuid>
    <ao:exact>ethinyl estradiol</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 12:38:04 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:79293219-D172-4E27-A045-D16B4F539C60">
    <ao:context rdf:resource="urn:domeoclient:uuid:E2AC08E4-8A5F-4E68-B2F1-20AFB690BAC7"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:A98BA61A-C2C5-4182-B0E9-6095CE94E0D1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-07 11:22:40 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB311B8D-11CB-4B44-BDC1-9641D482BE0D">
    <pav:createdOn>2014-07-13 11:18:02 -0400</pav:createdOn>
    <ao:prefix> and α1-acid glycoprotein. </ao:prefix>
    <ao:suffix> doses should be reduced in patients with liver disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS].</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>AB311B8D-11CB-4B44-BDC1-9641D482BE0D</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Risperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AB311B8D-11CB-4B44-BDC1-9641D482BE0D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D2E5F5D-2D44-4EC9-93CD-D558EE6CAD75">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>to patients with pulmonary arterial hypertension, lesser reductions than above in systolic and diastolic blood pressures were observed (a decrease in both of 2 mmHg).</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>sildenafil </ao:exact>
    <pav:createdOn>2014-07-07 09:40:26 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3D2E5F5D-2D44-4EC9-93CD-D558EE6CAD75"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B6D964C-5C7B-4A8B-91D1-71E48BED6297">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 12:46:12 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:A5674909-9644-497C-B284-D55E831FC413</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:D16208CB-7392-415A-8487-52928A419F00"/>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60E67B22-5DBF-4F42-9120-BC7E0F398FA0">
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 12:48:08 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:AE5EBB85-C1D9-438F-B2E8-17B61D972F3D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:body rdf:nodeID="Ndc3c3e907fd449d6886675778e001295"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:B4D55559-EA4E-4B39-A156-D764B9CB8614</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:017A9836-D985-4347-BFF0-9EBED8DB5CD1">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-13 11:17:02 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:55E92945-9B4A-406D-8BFF-54471B2E432E"/>
    <pav:lineageUri>urn:domeoserver:annotation:489A8473-952A-4034-A912-302A2847F038</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:195005D8-3CE9-43AD-A3D8-56739DB440A4">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <ao:exact>fluconazole</ao:exact>
    <pav:createdOn>2014-07-13 12:44:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:195005D8-3CE9-43AD-A3D8-56739DB440A4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> AUC after the administration of 50 mg of </ao:prefix>
    <domeo:uuid>195005D8-3CE9-43AD-A3D8-56739DB440A4</domeo:uuid>
    <ao:suffix>. The mean increase in ethinyl estradiol AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%).</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F9FE917E-CAFF-4C8B-B16B-BB0606212145">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-07 09:43:59 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:C29885C9-C34F-446F-88D0-5C6DE9D91033"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6A5356C-B181-4F61-AEF2-74464A340D7F">
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:C5FD329C-F801-4589-8147-439BFA776D12</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:15:53 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5FBE9544-4653-482C-B065-70CA3AA07309"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55E300CE-2A8F-42F4-9877-A49DDE4F3360">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:76A2A466-4D5D-4AA1-8114-FAD1FF0E6FC0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:7897E8BB-DD46-4B51-BE6D-8D92A1B57431</pav:lineageUri>
    <pav:createdOn>2014-07-07 11:24:12 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/1FCFC8E7-95A0-4188-9582-891391C2CFE6">
    <rdfs:label>fluconazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B8D94772-B85A-452F-91A5-C644F8298C08">
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:7E8BEB68-80C9-4767-BEC0-5810B8C956C0"/>
    <pav:createdOn>2014-07-07 09:58:55 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:34C83714-44E7-4047-8688-163A67040E44</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:789A1E1D-CA44-4410-B654-F6392AB94EDC">
    <ao:suffix> and α1-acid glycoprotein. The plasma protein binding of risperidone is 90%, and that of its major metabolite, 9-hydroxyrisperidone, is 77%. Neither risperidone nor 9-hydroxyrisperidone displaces each other from plasma binding sites. High therapeutic con</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>789A1E1D-CA44-4410-B654-F6392AB94EDC</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:789A1E1D-CA44-4410-B654-F6392AB94EDC"/>
    <pav:createdOn>2014-07-13 11:10:54 -0400</pav:createdOn>
    <ao:exact>albumin</ao:exact>
    <ao:prefix> is bound to </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:934B866B-AFCB-4F4A-A5CA-1B312B3088E1">
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:AD145E05-D965-40D9-8AB9-4C610AF8A665</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:A0EE858B-D738-4E79-B01E-E50A3141586B"/>
    <pav:createdOn>2014-07-13 11:15:01 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9645bb12c6664e0a859bf486d2521a23">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B622988-60A1-49F1-966B-8460BBF1DD4D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:18FCF895-E37C-47DC-9D3E-92CD602023DD</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-13 11:04:27 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:F3967C16-EC04-423B-908A-CF2BC1EC4011"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74FDA5BD-9C18-4F10-AC59-C5C75AA497C2">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:5CD942C6-D369-4ED6-B77B-FB216085FF48</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:F0CCA954-EB0E-4D16-9B00-C1E4BE4A989D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-07 11:24:14 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A95EA236-59E2-47FB-878A-81116D82930F">
    <ao:suffix> occurred at about 1 hour. Peak concentrations of 9-hydroxyrisperidone occurred at about 3 hours in extensive metabolizers, and 17 hours in poor metabolizers. Steady-state concentrations of risperidone are reached in 1 day in extensive metabolizers and w</ao:suffix>
    <domeo:uuid>A95EA236-59E2-47FB-878A-81116D82930F</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A95EA236-59E2-47FB-878A-81116D82930F"/>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily). Following oral administration of solution or tablet, mean peak plasma concentrations of </ao:prefix>
    <pav:createdOn>2014-07-13 11:10:15 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:99E97745-423E-4818-BFC6-3F67C8BF2A87">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:EAD485AF-D5DA-435A-B47D-F022CCE0E626</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:8ED4F58C-10A8-4F3A-8776-FD6D08A25610"/>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-13 11:11:00 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2A93D3C-935C-417F-BE1B-282EDBEB8D85">
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:14:04 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:12676179-27AE-44BF-86DE-5AE7A37D1457</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:56FE6B9A-96B3-43BC-A4E1-A9AFE78680CE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EEDA4663-FBED-4C68-848C-30943B88C061">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:10:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <domeo:uuid>EEDA4663-FBED-4C68-848C-30943B88C061</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EEDA4663-FBED-4C68-848C-30943B88C061"/>
    <ao:suffix> are reached in 1 day in extensive metabolizers and would be expected to reach steady-state in about 5 days in poor metabolizers. Steady-state concentrations of 9-hydroxyrisperidone are reached in 5 to 6 days (measured in extensive metabolizers).</ao:suffix>
    <ao:prefix> occurred at about 3 hours in extensive metabolizers, and 17 hours in poor metabolizers. Steady-state concentrations of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C5023B49-22AF-4880-9F9A-B1FCB16EAE71">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <domeo:uuid>C5023B49-22AF-4880-9F9A-B1FCB16EAE71</domeo:uuid>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C5023B49-22AF-4880-9F9A-B1FCB16EAE71"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> 50 mg once daily for 10 days in 10 healthy women. There was no significant difference in ethinyl estradiol or </ao:suffix>
    <ao:prefix>Oral contraceptives were administered as a single dose both before and after the oral administration of </ao:prefix>
    <pav:createdOn>2014-07-13 12:42:01 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0124DF91-B793-47E7-9547-2BF080146FA7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <pav:createdOn>2014-07-13 11:12:20 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix>, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug results from the combined concentrations of risperidone plus 9-hydroxyrisperidone.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0124DF91-B793-47E7-9547-2BF080146FA7"/>
    <domeo:uuid>0124DF91-B793-47E7-9547-2BF080146FA7</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6DDA4ED5-743F-4C12-93A8-37B2366FF364">
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:135F1FE6-83FC-4E58-95A7-4C08AED291BA"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:341C8689-0903-4B8F-836F-B52DFF733FFD</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-13 11:17:38 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.1alpha-050">
    <foafx:homepage></foafx:homepage>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <foafx:build>050</foafx:build>
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
    <foafx:version>2.1alpha</foafx:version>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E804A110-85A5-4650-B960-F11AB9FD25A2">
    <ao:prefix> (10 mcg/mL), and </ao:prefix>
    <ao:exact>carbamazepine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance.</ao:suffix>
    <pav:createdOn>2014-07-13 11:11:36 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E804A110-85A5-4650-B960-F11AB9FD25A2"/>
    <domeo:uuid>E804A110-85A5-4650-B960-F11AB9FD25A2</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:86692ABC-62BE-4895-A4EF-50FCB21327B2">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:86692ABC-62BE-4895-A4EF-50FCB21327B2"/>
    <domeo:uuid>86692ABC-62BE-4895-A4EF-50FCB21327B2</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> to interfere with metabolism of other drugs metabolized by CYP 2D6. Relatively weak binding of risperidone to the enzyme suggests this is unlikely [see 7 DRUG INTERACTIONS].</ao:suffix>
    <ao:exact>risperidone</ao:exact>
    <ao:prefix> [see 7 DRUG INTERACTIONS]. It would also be possible for </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:16:08 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:137A1951-AA86-4074-9581-B011801B955F">
    <pav:createdOn>2014-07-07 09:39:42 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:5FD113AB-8FB6-4F29-B1BE-0A776992E0B0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E08DAB4-201F-48CD-8ACA-375750DA65B1">
    <ao:prefix>concentrations when co-administered with </ao:prefix>
    <ao:exact>sildenafil </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3E08DAB4-201F-48CD-8ACA-375750DA65B1"/>
    <ao:suffix>(50 mg) to healthy volunteers.</ao:suffix>
    <pav:createdOn>2014-07-07 11:22:56 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D22E6FA-B90D-49C2-B42F-B8122D48D82A">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:462DD4AC-A4D5-481B-AE25-173C924C4620</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:62F3C932-C305-4581-AA4E-BB34C6D0F7D4"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 11:22:45 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A5A1F4E1-991C-4D93-AC6A-4DEDDF392601">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4CEC1749-9AA0-4FDA-B649-6B3CDED4298A"/>
    <pav:lineageUri>urn:domeoserver:annotation:7920C548-5100-46DE-B19C-AFACF431A0C2</pav:lineageUri>
    <pav:createdOn>2014-07-13 12:56:07 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3BEBBBC1-7503-4FA0-9B16-ED708F2AE108">
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:371BCC12-3242-4854-9882-2DB2B2EE1A70"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:2A576179-7248-4360-B213-E95632A0489F</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:38:53 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:10BB95F9-1856-4D70-9976-235CE8AD3D39">
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lastSavedOn>2014-07-07 11:36:14 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Nb929a74c378148db97fc9d4734a3edf3"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:8F3CF3D9-AADE-4A86-BD42-2924B3D6A406</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdOn>2014-07-07 11:36:13 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:2D04CBBE-379A-4D9F-BDD4-AA3663CD4669"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62F3C932-C305-4581-AA4E-BB34C6D0F7D4">
    <domeo:uuid></domeo:uuid>
    <ao:prefix>exposure without concomitant medication is shown to be 5-fold higher at a dose of 80 mg </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-07 11:22:45 -0400</pav:createdOn>
    <ao:exact>TID </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>compared to its exposure at a dose of 20 mg </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:62F3C932-C305-4581-AA4E-BB34C6D0F7D4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C02BE13-5688-4657-A7A7-6A459283AEB2">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:1554FCFD-7477-413C-879A-913DFFAB5886"/>
    <pav:createdOn>2014-07-07 11:24:07 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:A431D5CB-5994-440B-99C7-32C2F2EC8DE9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:043FCC7B-7CBD-4BE5-9962-3F6CF2B132DB">
    <pav:createdOn>2014-07-13 11:09:21 -0400</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix>Pharmacokinetic studies showed that </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> oral solution is bioequivalent to risperidone tablets.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:043FCC7B-7CBD-4BE5-9962-3F6CF2B132DB"/>
    <domeo:uuid>043FCC7B-7CBD-4BE5-9962-3F6CF2B132DB</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FAD17173-A1D3-4A24-A29E-5999F0DFA8F4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-07 09:58:43 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FAD17173-A1D3-4A24-A29E-5999F0DFA8F4"/>
    <ao:suffix>Injection: The pharmacokinetic profile of REVATIO has been characterized following intravenous administration. A 10 mg dose of REVATIO Injection is predicted to provide a pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to t</ao:suffix>
    <ao:exact>REVATIO </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/E2F95CEA-24A5-407F-856C-8C142EEA5626">
    <rdfs:label>fluconazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C29885C9-C34F-446F-88D0-5C6DE9D91033">
    <ao:exact>sildenafil</ao:exact>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C29885C9-C34F-446F-88D0-5C6DE9D91033"/>
    <ao:prefix>s metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% of the parent drug. In healthy volunteers, plasma concentrations of this metabolite are approximately 40% of those seen for </ao:prefix>
    <ao:suffix>, so that the metabolite accounts for about 20% of sildenafil's pharmacologic effects. In patients with pulmonary arterial hypertension, however, the ratio of the metabolite to sildenafil is higher. Both sildenafil and the active metabolite have terminal</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-07 09:43:59 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:04EFF21D-F5C9-468D-BFA5-057DD08ABD00">
    <pav:createdOn>2014-07-13 11:11:36 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:9901869B-6CBE-4242-B8B1-1CE8B5D728FA</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:E804A110-85A5-4650-B960-F11AB9FD25A2"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:454E7688-A4B1-42BF-86B5-6E1A3C88986A">
    <ao:context rdf:resource="urn:domeoclient:uuid:EEDA4663-FBED-4C68-848C-30943B88C061"/>
    <pav:createdOn>2014-07-13 11:10:25 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:B5E9E5D3-CEDE-43AC-A6D0-E7513DB65222</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2C79BAB-965C-479E-824A-F2884B348419">
    <domeo:uuid>E2C79BAB-965C-479E-824A-F2884B348419</domeo:uuid>
    <pav:createdOn>2014-07-13 12:38:39 -0400</pav:createdOn>
    <ao:exact>Fluconazole</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E2C79BAB-965C-479E-824A-F2884B348419"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compared to placebo dosing. The individual AUC values of norethindrone decreased very slightly (&lt;5%) in 3 of the 21 subjects after fluconazole treatm</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3762570C-CF43-4DB9-B163-FAA6DAE60017">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-07 09:39:29 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:28EA3105-DAE4-4248-8C5A-EACDF44B4680"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:28EA3105-DAE4-4248-8C5A-EACDF44B4680">
    <ao:suffix>were reported.</ao:suffix>
    <ao:exact>ECG </ao:exact>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:28EA3105-DAE4-4248-8C5A-EACDF44B4680"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-07 09:39:29 -0400</pav:createdOn>
    <ao:prefix>to patients with pulmonary arterial hypertension, no clinically relevant effects on </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F5A4FF79-C22B-475D-8775-B7CA929DA67C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F5A4FF79-C22B-475D-8775-B7CA929DA67C"/>
    <pav:createdOn>2014-07-13 12:38:47 -0400</pav:createdOn>
    <ao:suffix> AUC of any individual subject in this study compared to placebo dosing. The individual AUC values of norethindrone decreased very slightly (&lt;5%) in 3 of the 21 subjects after fluconazole treatment.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>F5A4FF79-C22B-475D-8775-B7CA929DA67C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> treatment did not cause a decrease in the </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <ao:exact>ethinyl estradiol</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A361190A-A611-4162-AA47-4014AAEBA0B2">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 11:12:23 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7E52164F-6FEF-4A1A-A55B-01314BCEB19B"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:19172135-E2AA-4088-BCFD-164180C591A3</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:010AF63D-C71E-4A93-9F41-8E5764F068ED">
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:42:05 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:00CDF4D6-2271-4B2A-9836-98BD00E7E952"/>
    <pav:lineageUri>urn:domeoserver:annotation:451E9FBF-CD25-4B95-963D-2A293790A1B4</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A3DCC3AB-4469-4227-B682-6E7F65CD2A7A">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9D2EDEBD-1223-4650-A96C-6AA36F00C854"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F14E8BB4-85EC-49A7-B9E5-8976B448D19D">
    <ao:prefix>Age, gender, race, and renal and hepatic function were included as factors assessed in the population pharmacokinetic model to evaluate </ao:prefix>
    <ao:exact>sildenafil </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>pharmacokinetics in patients with PAH. The dataset available for the population pharmacokinetic evaluation contained a wide range of demographic data and laboratory parameters associated with hepatic and renal function. None of these factors had a signif</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F14E8BB4-85EC-49A7-B9E5-8976B448D19D"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-07 09:59:05 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9E010F58-AD7C-435C-B2DC-0F81F34B978E">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-07 11:37:21 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N1dedc17cc1ff4d1c8dc93f32fadfb815"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:6AED9017-2775-4A23-915C-FCB7842E4D54</pav:lineageUri>
    <pav:lastSavedOn>2014-07-07 11:37:25 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:CF3DBDD7-1816-4E91-BF27-7D21BEF67A06"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F557214F-193F-480C-8483-C59A8CFCD22E">
    <pav:createdOn>2014-07-13 11:09:17 -0400</pav:createdOn>
    <domeo:uuid>F557214F-193F-480C-8483-C59A8CFCD22E</domeo:uuid>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> from a tablet is 94% (CV=10%) when compared to a solution.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F557214F-193F-480C-8483-C59A8CFCD22E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix> is 70% (CV=25%). The relative oral bioavailability of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A29DA787-54E3-4422-B166-2BA6676BC91D">
    <pav:createdOn>2014-07-13 11:11:50 -0400</pav:createdOn>
    <ao:prefix> at 10 ng/mL and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A29DA787-54E3-4422-B166-2BA6676BC91D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <domeo:uuid>A29DA787-54E3-4422-B166-2BA6676BC91D</domeo:uuid>
    <ao:suffix> at 50 ng/mL, changes of unknown clinical significance.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5FD113AB-8FB6-4F29-B1BE-0A776992E0B0">
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5FD113AB-8FB6-4F29-B1BE-0A776992E0B0"/>
    <pav:createdOn>2014-07-07 09:39:42 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>TID sildenafil</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE972F8D-C1AD-46A9-B34B-1D883FDAF1EC">
    <pav:createdOn>2014-07-07 09:40:14 -0400</pav:createdOn>
    <ao:exact>sildenafil </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>to patients with systemic hypertension, the mean change from baseline in systolic and diastolic blood pressures was a decrease of 9.4 mmHg and 9.1 mmHg, respectively.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CE972F8D-C1AD-46A9-B34B-1D883FDAF1EC"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B743E18-8323-4761-B0A4-3B200C16F9BE">
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:9644563B-1E1E-4AF0-871E-E395B93BB653</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:14:31 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:16FE2F0D-3BF4-4708-9147-BD5159B47059"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE16BF01-AD42-444E-9A68-FEF6AED26815">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-07 09:39:36 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E5D76E00-F5D9-4E93-B3B6-47859812ACDF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9E21C61-063D-4F80-8E08-85865B387669">
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-07 09:36:49 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:8232EB8B-B7ED-4583-BE33-F0AD71DA4D1C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e143046812afe0146812eda990003">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:middlename></foafx:middlename>
    <foafx:email>nonexpert2@gmail.com</foafx:email>
    <foafx:firstname>nonexpert</foafx:firstname>
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <foafx:homepage></foafx:homepage>
    <foafx:title>nonexpert2</foafx:title>
    <foafx:name>nonexpert2</foafx:name>
    <rdfs:label>nonexpert2</rdfs:label>
    <foafx:lastname>2</foafx:lastname>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9B027AFC-3BAE-4FDC-889F-813F2AD35C5A">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D318A30A-F708-43F6-AB5B-A9D659E063BF"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EBCFB082-4C3F-4C27-B1B4-7DE7E01178ED">
    <ao:prefix>Administration of a single oral 200 mg dose of </ao:prefix>
    <ao:suffix> after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in flucon</ao:suffix>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EBCFB082-4C3F-4C27-B1B4-7DE7E01178ED"/>
    <domeo:uuid>EBCFB082-4C3F-4C27-B1B4-7DE7E01178ED</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 12:55:59 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/83E9958D-5BAA-415C-B14A-C204CC3ED68C">
    <rdfs:label>risperidone</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72C81315-5D14-41CA-AEB9-E23AC335F4C3">
    <domeo:uuid>72C81315-5D14-41CA-AEB9-E23AC335F4C3</domeo:uuid>
    <ao:exact>ethinyl estradiol</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> compared to similar placebo dosing. The mean AUCs of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:72C81315-5D14-41CA-AEB9-E23AC335F4C3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 12:38:31 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <ao:suffix> and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compar</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:83D060E5-70B4-4270-94D2-6FF812E77E78">
    <pav:createdOn>2014-07-13 11:12:03 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>83D060E5-70B4-4270-94D2-6FF812E77E78</domeo:uuid>
    <ao:suffix> to 9-hydroxyrisperidone by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, 9-hydroxyrisperidone, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug results fr</ao:suffix>
    <ao:prefix> is extensively metabolized in the liver. The main metabolic pathway is through hydroxylation of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:83D060E5-70B4-4270-94D2-6FF812E77E78"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EFE95BF7-1349-414E-B68F-6C5149A03072">
    <ao:exact>TID</ao:exact>
    <ao:prefix>exposure without concomitant medication is shown to be 5-fold higher at a dose of 80 mg TID compared to its exposure at a dose of 20 mg </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-07 11:22:43 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>. This concentration range covers the same increased sildenafil exposure observed in specifically-designed drug interaction studies with CYP3A inhibitors (except for potent inhibitors such as ketoconazole, itraconazole, and ritonavir).</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EFE95BF7-1349-414E-B68F-6C5149A03072"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:40519342-F06B-41D2-A39A-795BA218AF7B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 12:46:18 -0400</pav:createdOn>
    <ao:exact>cimetidine</ao:exact>
    <ao:suffix>, there was a significant decrease in fluconazole AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). However, the administration of cimetidine 600 mg to 900</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <domeo:uuid>40519342-F06B-41D2-A39A-795BA218AF7B</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:40519342-F06B-41D2-A39A-795BA218AF7B"/>
    <ao:prefix> 400 mg to six healthy male volunteers. After the administration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B475492-95FE-4CDD-81AE-94DFEEB91E11">
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 11:09:25 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:46780EA4-462F-4B55-AB22-23CB7FC82C80"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:D6AADC58-2D29-4DC9-83E4-5252DDC68D2C</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ECB23C3B-E835-480F-B541-EB5CBBAB2855">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ECB23C3B-E835-480F-B541-EB5CBBAB2855"/>
    <ao:suffix> 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.</ao:suffix>
    <domeo:uuid>ECB23C3B-E835-480F-B541-EB5CBBAB2855</domeo:uuid>
    <pav:createdOn>2014-07-13 12:46:33 -0400</pav:createdOn>
    <ao:exact>fluconazole</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4FCA7E7B-CC82-4455-94C0-73C09ED070C1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 12:34:41 -0400</pav:createdOn>
    <domeo:uuid>4FCA7E7B-CC82-4455-94C0-73C09ED070C1</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-20.txt.html</ao:hasSource>
    <ao:exact>sertraline</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4FCA7E7B-CC82-4455-94C0-73C09ED070C1"/>
    <ao:suffix> and the following inactive ingredients: dibasic calcium phosphate dihydrate, hydroxypropyl cellulose, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, talc, and titanium dioxide.</ao:suffix>
    <ao:prefix> hydrochloride equivalent to 25, 50, 100, 150 and 200 mg of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FB0C633B-9063-4FD0-91E9-2810CF1C157A">
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-07 09:40:26 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:3D2E5F5D-2D44-4EC9-93CD-D558EE6CAD75"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8543469A-E725-45C1-A0A3-93FAB55D1DD5">
    <ao:prefix> and higher </ao:prefix>
    <ao:suffix> concentrations than poor metabolizers, the pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, are similar in extensive and poor metabolizers.</ao:suffix>
    <domeo:uuid>8543469A-E725-45C1-A0A3-93FAB55D1DD5</domeo:uuid>
    <pav:createdOn>2014-07-13 11:13:40 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8543469A-E725-45C1-A0A3-93FAB55D1DD5"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2B951EF5-B48C-4B58-B273-480990730DEA">
    <ao:suffix> have not been evaluated, but observations in a modest number (N≅70) of poor metabolizers given risperidone do not suggest important differences between poor and extensive metabolizers. Second, co-administration of known enzyme inducers (e.g., carbamazep</ao:suffix>
    <pav:createdOn>2014-07-13 11:15:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>quinidine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2B951EF5-B48C-4B58-B273-480990730DEA"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> in patients receiving </ao:prefix>
    <domeo:uuid>2B951EF5-B48C-4B58-B273-480990730DEA</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/851B37FE-C029-42CD-9AFE-2CD0906FA393">
    <rdfs:label>fluconazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E73E8FF7-7FA2-47F3-B0B1-14D1640DDBF7">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:469138F3-F092-499E-AF0F-B2CB920DF026</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:10:54 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:789A1E1D-CA44-4410-B654-F6392AB94EDC"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:49F8A244-9291-40F9-AE95-B64DDF5E624D">
    <ao:suffix> are both approximately 96% bound to plasma proteins. Protein binding is independent of total drug concentrations.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-07 09:57:03 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:49F8A244-9291-40F9-AE95-B64DDF5E624D"/>
    <ao:exact>metabolite</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D7139F9-BDC3-437F-A5A1-D75EDAC972B0">
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:B3435A02-DBAF-4D33-9A80-3B78037721AE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:07:46 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:18699EA6-5F06-460B-B2AD-992A44EC2FCD</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF3DBDD7-1816-4E91-BF27-7D21BEF67A06">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:exact>In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC</ao:exact>
    <pav:createdOn>2014-07-07 11:37:21 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>CF3DBDD7-1816-4E91-BF27-7D21BEF67A06</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CF3DBDD7-1816-4E91-BF27-7D21BEF67A06"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/AFDFD2C0-7545-4E19-ABAA-7E48CFD82223">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluconazole</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1554FCFD-7477-413C-879A-913DFFAB5886">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-07 11:24:07 -0400</pav:createdOn>
    <ao:exact>sildenafil </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:suffix>(100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.</ao:suffix>
    <ao:prefix>, a CYP3A inhibitor, at steady state (1200 mg TID) with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1554FCFD-7477-413C-879A-913DFFAB5886"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E17F3ACA-8486-4702-886B-6FA2562FDEFF">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E17F3ACA-8486-4702-886B-6FA2562FDEFF"/>
    <ao:prefix> AUC was 6% (range: -47 to 108%) and </ao:prefix>
    <ao:exact>levonorgestrel</ao:exact>
    <pav:createdOn>2014-07-13 12:44:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> AUC increased 17% (range: -33 to 141%).</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>E17F3ACA-8486-4702-886B-6FA2562FDEFF</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A0645479-B3CA-4505-B451-B003C3B19554">
    <pav:createdOn>2014-07-13 12:44:25 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:EABDAFD6-3CCF-4D2C-BD80-C1DB3A591C0B</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:195005D8-3CE9-43AD-A3D8-56739DB440A4"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:159DCA30-3727-4241-9440-301E40381956">
    <domeo:uuid>159DCA30-3727-4241-9440-301E40381956</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> (100 mcg/mL), </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>warfarin</ao:exact>
    <pav:createdOn>2014-07-13 11:11:31 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:159DCA30-3727-4241-9440-301E40381956"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2EC8E075-F7E3-4259-A656-99D292E9F0A4">
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 11:12:20 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:6A45E1E3-7270-4950-9185-AED9AF04A2E4</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:0124DF91-B793-47E7-9547-2BF080146FA7"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E5D76E00-F5D9-4E93-B3B6-47859812ACDF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-07 09:39:36 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>ildenafil</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E5D76E00-F5D9-4E93-B3B6-47859812ACDF"/>
    <ao:exact>TID s</ao:exact>
    <ao:prefix>After chronic dosing of 80 mg </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:984E4D2D-A998-4068-9BF7-F709348DD1B2">
    <ao:exact>risperidone</ao:exact>
    <domeo:uuid>984E4D2D-A998-4068-9BF7-F709348DD1B2</domeo:uuid>
    <ao:prefix>Elderly: In healthy elderly subjects, renal clearance of both </ao:prefix>
    <ao:suffix> and 9-hydroxyrisperidone was decreased, and elimination half-lives were prolonged compared to young healthy subjects. Dosing should be modified accordingly in the elderly patients [see 2 DOSAGE AND ADMINISTRATION].</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:984E4D2D-A998-4068-9BF7-F709348DD1B2"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:18:21 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A412DBFC-2FE0-43FA-A538-B84D822A5BFD">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:suffix>pharmacologic effects. In patients with pulmonary arterial hypertension, however, the ratio of the metabolite to sildenafil is higher. Both sildenafil and the active metabolite have terminal half-lives of about 4 hours.</ao:suffix>
    <pav:createdOn>2014-07-07 09:44:07 -0400</pav:createdOn>
    <ao:prefix>, so that the metabolite accounts for about 20% of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A412DBFC-2FE0-43FA-A538-B84D822A5BFD"/>
    <ao:exact>sildenafil's </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5BA6BC8B-1F30-4288-9D03-060F552BAA12">
    <pav:createdOn>2014-07-13 11:16:53 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:DDA9B5AE-040F-439A-82F9-BF46844F39FC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:1BF82CCC-CD60-4AB5-8C1B-4176DC1A85F3"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/A36E11B0-6726-4AD1-ACC7-4E8E59A350EB">
    <rdfs:label>levonorgestrel</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6373</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6B6560EB-DD3A-4FD9-ACE8-690CA260DD8B">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:45DFA268-E20B-41A7-BE0C-703868597D0E</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:76258D2D-1630-4254-82ED-C3434163EAE3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:15:09 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N962525f6f4b447b9ae5ef01bad49d655">
    <domeo:sets rdf:resource="urn:pddi:uuid:A3DCC3AB-4469-4227-B682-6E7F65CD2A7A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB3EAD78-45A5-439B-B26A-FE0BB9EDCBD0">
    <domeo:uuid>AB3EAD78-45A5-439B-B26A-FE0BB9EDCBD0</domeo:uuid>
    <ao:exact>Fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 12:56:13 -0400</pav:createdOn>
    <ao:prefix> increased 32% ± 17% (range: 16 to 72%). </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AB3EAD78-45A5-439B-B26A-FE0BB9EDCBD0"/>
    <ao:suffix> half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours. (See PRECAUTIONS.)</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:57242808-9748-4ED3-908E-E0054E0C8BBE">
    <domeo:uuid>57242808-9748-4ED3-908E-E0054E0C8BBE</domeo:uuid>
    <ao:suffix> in 24 healthy male volunteers.</ao:suffix>
    <ao:prefix> 200 mg) did not affect the bioavailability or pharmacokinetics of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:57242808-9748-4ED3-908E-E0054E0C8BBE"/>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 12:46:37 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05BFBD66-D24D-4F61-89C5-4EDDE7B6040C">
    <pav:createdOn>2014-07-13 11:10:51 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:CA7C94FF-7470-4B26-A1E1-5C8247C8F0FC</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9BB046B1-5949-4043-9525-70D01EC3816C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FD9D4BD5-A390-4CD6-8FF4-21ABE76D596A">
    <pav:lineageUri>urn:domeoserver:annotation:4B02B1E0-9F20-40AA-9E20-12AD253C4462</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:CB01A892-8D67-4A38-8CA4-2D230875A1F6"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 11:17:12 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1F12731E-6D41-4E27-83E3-C87822424FCA">
    <ao:context rdf:resource="urn:domeoclient:uuid:F14E8BB4-85EC-49A7-B9E5-8976B448D19D"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-07 09:59:05 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:35639159-ED9C-4B53-8BA3-5D1C355CF374</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA839309-7C8B-4446-A5C1-08694E7B8482">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>9-</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FA839309-7C8B-4446-A5C1-08694E7B8482"/>
    <pav:createdOn>2014-07-13 11:09:57 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix>, its major metabolite, </ao:prefix>
    <domeo:uuid>FA839309-7C8B-4446-A5C1-08694E7B8482</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EFBA3663-4C52-45BA-895B-7EB3C0A4DA3A">
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:1B4D9B85-636E-45EE-9796-1A7AE7E45DCF"/>
    <pav:createdOn>2014-07-13 11:11:43 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:03C6457D-A506-405A-9290-D5818D79A053</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72594949-CA92-4CEF-8CB6-0072661759A0">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-13 12:38:31 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:72C81315-5D14-41CA-AEB9-E23AC335F4C3"/>
    <pav:lineageUri>urn:domeoserver:annotation:4A02C183-A585-4567-848A-3878478E06F5</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C0DCB0F4-61CC-48CE-8688-567F2327B321">
    <ao:suffix> 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.</ao:suffix>
    <domeo:uuid>C0DCB0F4-61CC-48CE-8688-567F2327B321</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C0DCB0F4-61CC-48CE-8688-567F2327B321"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>cimetidine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). However, the administration of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 12:46:27 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B0AC894E-27E2-43D9-BFEB-167E8117247A">
    <ao:prefix> hydrochloride is supplied for oral administration as scored tablets containing </ao:prefix>
    <domeo:uuid>B0AC894E-27E2-43D9-BFEB-167E8117247A</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-20.txt.html</ao:hasSource>
    <ao:exact>sertraline</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B0AC894E-27E2-43D9-BFEB-167E8117247A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> hydrochloride equivalent to 25, 50, 100, 150 and 200 mg of sertraline and the following inactive ingredients: dibasic calcium phosphate dihydrate, hydroxypropyl cellulose, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol</ao:suffix>
    <pav:createdOn>2014-07-13 12:34:38 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3D2A83E-9B62-495D-A7E7-A17FEF5E2561">
    <domeo:uuid>F3D2A83E-9B62-495D-A7E7-A17FEF5E2561</domeo:uuid>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>The mechanism of action of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix>, as with other drugs used to treat schizophrenia, is unknown. However, it has been proposed that the drug’s therapeutic activity in schizophrenia is mediated through a combination of dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism.</ao:suffix>
    <pav:createdOn>2014-07-13 11:04:07 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F3D2A83E-9B62-495D-A7E7-A17FEF5E2561"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:420A77EC-3CAE-4EA3-B428-B635FA4A9F5D">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:11:13 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:1734C6CD-F7E3-40D2-B440-4C5D8B428556</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:804C4BF7-B45B-4CC2-BD44-707AAD50F219"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8214D15C-5AF1-47D0-A63C-30543353403D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 12:37:44 -0400</pav:createdOn>
    <domeo:uuid>8214D15C-5AF1-47D0-A63C-30543353403D</domeo:uuid>
    <ao:prefix> dosing resulted in small increases in the mean AUCs of </ao:prefix>
    <ao:exact>ethinyl estradiol</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8214D15C-5AF1-47D0-A63C-30543353403D"/>
    <ao:suffix> and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cau</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9D2EDEBD-1223-4650-A96C-6AA36F00C854">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/7C1B3FD3-CA8D-4D2F-B094-F0DB74BF2108"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/964F2661-87EF-4D00-87C8-D1C5E12C0ECB"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/8FE58707-AFDD-4F32-9EA8-03EC3BF4D67B">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/136411</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sildenafil</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ECF8E578-9A91-41E0-91AC-502E097E5A11">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-07 11:23:40 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>administration.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ECF8E578-9A91-41E0-91AC-502E097E5A11"/>
    <ao:prefix>Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral </ao:prefix>
    <ao:exact>sildenafil </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46780EA4-462F-4B55-AB22-23CB7FC82C80">
    <ao:suffix> tablets.</ao:suffix>
    <ao:prefix> oral solution is bioequivalent to </ao:prefix>
    <domeo:uuid>46780EA4-462F-4B55-AB22-23CB7FC82C80</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:46780EA4-462F-4B55-AB22-23CB7FC82C80"/>
    <pav:createdOn>2014-07-13 11:09:25 -0400</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58C4B9F6-E8BB-4567-9FF2-3D87C6E9284C">
    <domeo:uuid>58C4B9F6-E8BB-4567-9FF2-3D87C6E9284C</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:58C4B9F6-E8BB-4567-9FF2-3D87C6E9284C"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 12:45:51 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16393981-08BF-477D-ACB9-8FB804E50D0C">
    <ao:context rdf:resource="urn:domeoclient:uuid:49F8A244-9291-40F9-AE95-B64DDF5E624D"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 09:57:03 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:5D5E7705-CD13-417B-BE4C-010E6D19EB36</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50649F2A-1F77-4AC3-AA05-9C465AAF3D79">
    <ao:suffix> pharmacokinetics in patients with PAH.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:prefix> in patients with PAH. The dataset available for the population pharmacokinetic evaluation contained a wide range of demographic data and laboratory parameters associated with hepatic and renal function. None of these factors had a significant impact on </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-07 09:59:10 -0400</pav:createdOn>
    <ao:exact>sildenafil </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:50649F2A-1F77-4AC3-AA05-9C465AAF3D79"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BD1E279-39ED-4853-AF2E-BE56BEB4AF03">
    <pav:lineageUri>urn:domeoserver:annotation:7687B2A2-948F-4E07-9BC1-43216AD31878</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:11:31 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:159DCA30-3727-4241-9440-301E40381956"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:30818391-5098-4A86-BF01-5AB0C0597335">
    <ao:exact>s</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-07-13 11:11:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> displaces each other from plasma binding sites. High therapeutic concentrations of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:30818391-5098-4A86-BF01-5AB0C0597335"/>
    <domeo:uuid>30818391-5098-4A86-BF01-5AB0C0597335</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AE5EBB85-C1D9-438F-B2E8-17B61D972F3D">
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 12:48:08 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AE5EBB85-C1D9-438F-B2E8-17B61D972F3D"/>
    <ao:exact>However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male</ao:exact>
    <ao:suffix> volunteers</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>AE5EBB85-C1D9-438F-B2E8-17B61D972F3D</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:464ED203-77EC-4EFC-873A-7853A308DCA5">
    <ao:context rdf:resource="urn:domeoclient:uuid:7F63A36F-F819-4E40-9C8A-C518B5519787"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:17:56 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:A434E784-EF19-4D9F-9D9A-D71E320A8599</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf99da3c207b0419c8325728d0058b71e">
    <domeo:sets rdf:resource="urn:pddi:uuid:E8B9127A-D513-4699-BEA0-07E095BADF5D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:34472B29-EA4E-45E5-84B2-2EEE556610B6">
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:B294F73B-169E-4106-90EF-3C87099953E8"/>
    <ao:body rdf:nodeID="N16510bbf973a455da2d0e9018e7cbe64"/>
    <pav:lineageUri>urn:domeoserver:annotation:29BBE1A3-B55A-462F-A387-1BC5EE901EF7</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:29:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0CE6C620-40B4-4E55-8185-8A319ECD6D71">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:553A6608-733A-477E-BDCB-F0D16F1054E3"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:54B9529D-9030-4194-B66A-D7ECCBABED1F">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-07 09:37:41 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:DBBBE91C-3E2F-469A-9254-58328E372FEA"/>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E8B9127A-D513-4699-BEA0-07E095BADF5D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:29BA1C64-71E4-4437-B3E3-C16FF494B3CA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E76D782E-ADBF-42D0-9CCA-8944F07D22DA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:B98C3482-C44D-4C61-ACC3-D277890BCE91"/>
    <pav:lineageUri>urn:domeoserver:annotation:D0DD21B4-2DEA-49DA-B4BC-07501CC0DD24</pav:lineageUri>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 11:23:25 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14556CC1-0C55-47A6-8175-973C292639CC">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:71D2AAB3-67A2-451B-BC9A-B33DCA934E67</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:16:08 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:86692ABC-62BE-4895-A4EF-50FCB21327B2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:532294F2-A52D-4732-85C4-0F955156A615">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:10:06 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily). Following oral administration of solution or tablet, mean peak plasma concentrations of risperidone occurred at about 1 hour. Peak concentrations of 9-hydroxyrisp</ao:suffix>
    <domeo:uuid>532294F2-A52D-4732-85C4-0F955156A615</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> plus </ao:prefix>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:532294F2-A52D-4732-85C4-0F955156A615"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9A220CC1-B0E4-46E3-92ED-BA102CB9A99F">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/E2F95CEA-24A5-407F-856C-8C142EEA5626"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D17A3686-1703-468A-9054-837449C245F1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:799D7550-4333-4600-A69B-DE23093443A4">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F049BA4A-8DAF-49C1-ABA1-6E76A2F6DA6B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97C1D6A3-E462-4C1F-8DD6-513D5AD2268A">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F63AE259-E4D8-48C8-9143-FADBBFAD548B"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-13 11:07:54 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:693FA6F8-074D-41A3-9AF3-2256D761F345</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8EAC93E7-05D8-439B-86B4-7B47CB07E8D8">
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:17:15 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:12670ED8-C472-4DF9-A553-567C7F4720E9</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:70B9E8E9-06ED-4420-9CDE-4E0F36F57CC9"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A7AE105-ADC2-416B-AD5B-0B0B1DB2A2E2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 12:38:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> decreased very slightly (&lt;5%) in 3 of the 21 subjects after </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8A7AE105-ADC2-416B-AD5B-0B0B1DB2A2E2"/>
    <domeo:uuid>8A7AE105-ADC2-416B-AD5B-0B0B1DB2A2E2</domeo:uuid>
    <ao:exact>fluconazole</ao:exact>
    <ao:suffix> treatment.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3F94F7A-3299-4ECD-8A0C-54D9B0E17A6D">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F3F94F7A-3299-4ECD-8A0C-54D9B0E17A6D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, whereas poor CYP 2D6 metabolizers convert it much more slowly. Although extensive metabolizers have lower risperidone and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of risperidone and 9-hydroxyrisperidone co</ao:suffix>
    <domeo:uuid>F3F94F7A-3299-4ECD-8A0C-54D9B0E17A6D</domeo:uuid>
    <ao:prefix> rapidly into </ao:prefix>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:13:30 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3A07EF3E-A1DF-4E0E-952B-5422EC6E9B3D">
    <ao:suffix>concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>sildenafil </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:prefix>(800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-07 11:22:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3A07EF3E-A1DF-4E0E-952B-5422EC6E9B3D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne98fefd482bf4efaa1ebf4ad1bb5ff2b">
    <domeo:sets rdf:resource="urn:pddi:uuid:799D7550-4333-4600-A69B-DE23093443A4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:735CA4BD-A16D-4729-BFC3-96D72BFE5B0B">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-07 11:23:01 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:007F6835-1CAF-4F0B-8BFD-311D8BFD8926"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:996DAC66-98E7-4BAE-90CA-B2474D43F8E1</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F1504F1A-B189-4B6A-9973-4A17775240C5">
    <rdfs:label>9-hydroxyrisperidone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/679314</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4EEAF739-3D04-465D-8AC0-35EAE4B00AE0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:3D8D67C2-6E18-4F0E-AEDD-1DFCE48220A1</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:F3FEE8D2-9817-490A-AF14-CC53E5ADFBF2"/>
    <pav:createdOn>2014-07-13 12:35:54 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/94DFD21D-D749-4F5E-AE57-CF5CE30BA0D9">
    <rdfs:label>fluconazole</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DC200567-4E8F-495B-9D13-A2A04A7A47EC">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/83E9958D-5BAA-415C-B14A-C204CC3ED68C"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F1504F1A-B189-4B6A-9973-4A17775240C5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8ED4F58C-10A8-4F3A-8776-FD6D08A25610">
    <domeo:uuid>8ED4F58C-10A8-4F3A-8776-FD6D08A25610</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8ED4F58C-10A8-4F3A-8776-FD6D08A25610"/>
    <ao:suffix> is 90%, and that of its major metabolite, 9-hydroxyrisperidone, is 77%. Neither risperidone nor 9-hydroxyrisperidone displaces each other from plasma binding sites. High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), an</ao:suffix>
    <pav:createdOn>2014-07-13 11:11:00 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> and α1-acid glycoprotein. The plasma protein binding of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:43E08535-8340-472C-92D9-100ECFA2CB93">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/AFDFD2C0-7545-4E19-ABAA-7E48CFD82223"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/CE1B6F16-57BD-40EB-AB83-B1A40576F8C0"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N65fa39a768be45569cc90c27aaec1f83">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5F8E4E79-C59A-410E-ACD6-41B9C532F968">
    <ao:context rdf:resource="urn:domeoclient:uuid:806597EC-5BAB-46E0-96D6-B25563A80A8C"/>
    <pav:createdOn>2014-07-13 11:14:57 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:FDE2CC52-F5FC-4C63-AEAD-C53C36960021</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6BF6E19B-3833-4401-A589-B16E9522C485">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-07 09:58:53 -0400</pav:createdOn>
    <ao:prefix>Injection: The pharmacokinetic profile of REVATIO has been characterized following intravenous administration. A 10 mg dose of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>Injection is predicted to provide a pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose.</ao:suffix>
    <ao:exact>REVATIO </ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6BF6E19B-3833-4401-A589-B16E9522C485"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95AEC430-A2F4-4B0D-B623-70050D7B891E">
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:CC861D6D-4076-4F69-B134-B404C685F91A"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:18:24 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:EB8C6594-359A-42D0-A03E-A9374296DDDA</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7CBD8092-1453-4994-9F29-22622E743A15">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/B7CB635F-4EBF-434B-9159-71DC46A33588"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/94DFD21D-D749-4F5E-AE57-CF5CE30BA0D9"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD57239D-3225-4F0C-8054-FBD32976EE0C">
    <ao:exact>risperidone</ao:exact>
    <ao:prefix> in subjects with liver disease were comparable to those in young healthy subjects, the mean free fraction of </ao:prefix>
    <ao:suffix> in plasma was increased by about 35% because of the diminished concentration of both albumin and α1-acid glycoprotein. Risperidone doses should be reduced in patients with liver disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS].</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AD57239D-3225-4F0C-8054-FBD32976EE0C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:17:48 -0400</pav:createdOn>
    <domeo:uuid>AD57239D-3225-4F0C-8054-FBD32976EE0C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56FE6B9A-96B3-43BC-A4E1-A9AFE78680CE">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:56FE6B9A-96B3-43BC-A4E1-A9AFE78680CE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> to </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> [see 7 DRUG INTERACTIONS]. This occurs with quinidine, giving essentially all recipients a risperidone pharmacokinetic profile typical of poor metabolizers. The therapeutic benefits and adverse effects of risperidone in patients receiving quinidine have</ao:suffix>
    <pav:createdOn>2014-07-13 11:14:04 -0400</pav:createdOn>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <domeo:uuid>56FE6B9A-96B3-43BC-A4E1-A9AFE78680CE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5F4EA581-2F5C-4FF1-8DA3-D5101E760F69">
    <ao:prefix> and its major metabolite, </ao:prefix>
    <ao:suffix> [see 12 CLINICAL PHARMACOLOGY]. Antagonism at receptors other than D2 and 5HT2 [see 12 CLINICAL PHARMACOLOGY] may explain some of the other effects of risperidone.</ao:suffix>
    <pav:createdOn>2014-07-13 11:28:14 -0400</pav:createdOn>
    <domeo:uuid>5F4EA581-2F5C-4FF1-8DA3-D5101E760F69</domeo:uuid>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5F4EA581-2F5C-4FF1-8DA3-D5101E760F69"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:64792593-BEAB-4B65-88FB-A2254663F469">
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:C65DDEB0-B97A-4B57-9CA0-73F44448001C</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:DFB0D433-995A-4EB5-B9CC-EAE5A0C16DEA"/>
    <pav:createdOn>2014-07-13 11:12:29 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0F95BD67-87EE-4AA9-A33E-A0BCF7921FF0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (ran</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <ao:exact>rifampin</ao:exact>
    <domeo:uuid>0F95BD67-87EE-4AA9-A33E-A0BCF7921FF0</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 12:56:00 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0F95BD67-87EE-4AA9-A33E-A0BCF7921FF0"/>
    <ao:prefix> after 15 days of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf74e64afe6d446b49cb63347d5d462f0">
    <domeo:sets rdf:resource="urn:pddi:uuid:125C14DB-1F35-4667-846F-F789D6D0AFCF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0991F050-6152-45E8-8D40-DC901E368C9E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0991F050-6152-45E8-8D40-DC901E368C9E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> and its active metabolite decreased by 60% compared to young healthy subjects. Risperidone doses should be reduced in patients with renal disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS].</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <domeo:uuid>0991F050-6152-45E8-8D40-DC901E368C9E</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:17:24 -0400</pav:createdOn>
    <ao:prefix>Renal Impairment: In patients with moderate to severe renal disease, clearance of the sum of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C2471146-B114-47FF-BB78-F58B6158FB99">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DC200567-4E8F-495B-9D13-A2A04A7A47EC"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/ED3BCC98-B0FE-4421-B54B-7B2414CF4328">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7514</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>norethindrone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D78CEABF-EE24-4AFF-81A9-B148050EFE16">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D78CEABF-EE24-4AFF-81A9-B148050EFE16"/>
    <ao:prefix>, </ao:prefix>
    <domeo:uuid>D78CEABF-EE24-4AFF-81A9-B148050EFE16</domeo:uuid>
    <ao:suffix>, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>phenytoin</ao:exact>
    <pav:createdOn>2014-07-13 11:15:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:29BA1C64-71E4-4437-B3E3-C16FF494B3CA">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/5AC4FDB3-99BB-4CC2-9A03-87893DB04756"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F4851EA8-C391-4F16-B8F8-81A3F2688015"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7EA46EFB-1A94-409D-B432-24203EA5400F">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:8A7AE105-ADC2-416B-AD5B-0B0B1DB2A2E2"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:0DE5D981-90C9-4EFB-8436-D8AEB6978507</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 12:38:56 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CB01A892-8D67-4A38-8CA4-2D230875A1F6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <ao:prefix> was about 21 hours (CV=20%) in extensive metabolizers and 30 hours (CV=25%) in poor metabolizers. The pharmacokinetics of </ao:prefix>
    <pav:createdOn>2014-07-13 11:17:12 -0400</pav:createdOn>
    <ao:suffix> and 9-hydroxyrisperidone combined, after single and multiple doses, were similar in extensive and poor metabolizers, with an overall mean elimination half-life of about 20 hours.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CB01A892-8D67-4A38-8CA4-2D230875A1F6"/>
    <domeo:uuid>CB01A892-8D67-4A38-8CA4-2D230875A1F6</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC861D6D-4076-4F69-B134-B404C685F91A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> and </ao:prefix>
    <domeo:uuid>CC861D6D-4076-4F69-B134-B404C685F91A</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> was decreased, and elimination half-lives were prolonged compared to young healthy subjects. Dosing should be modified accordingly in the elderly patients [see 2 DOSAGE AND ADMINISTRATION].</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CC861D6D-4076-4F69-B134-B404C685F91A"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <pav:createdOn>2014-07-13 11:18:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7AF3A49F-90C3-4D03-97CB-74AE03BF7C86">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:F557214F-193F-480C-8483-C59A8CFCD22E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:0C24008F-78E2-49EE-9161-71EEB60D2ECD</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 11:09:17 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/E4072F00-AC18-479B-BBF5-FE87E12CA45B">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>cimetidine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N16510bbf973a455da2d0e9018e7cbe64">
    <domeo:sets rdf:resource="urn:pddi:uuid:C2471146-B114-47FF-BB78-F58B6158FB99"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:806597EC-5BAB-46E0-96D6-B25563A80A8C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:806597EC-5BAB-46E0-96D6-B25563A80A8C"/>
    <ao:prefix> [see 7 DRUG INTERACTIONS]. This occurs with quinidine, giving essentially all recipients a </ao:prefix>
    <domeo:uuid>806597EC-5BAB-46E0-96D6-B25563A80A8C</domeo:uuid>
    <ao:suffix> pharmacokinetic profile typical of poor metabolizers. The therapeutic benefits and adverse effects of risperidone in patients receiving quinidine have not been evaluated, but observations in a modest number (N≅70) of poor metabolizers given risperidone </ao:suffix>
    <ao:exact>risperidone</ao:exact>
    <pav:createdOn>2014-07-13 11:14:57 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7FE9AC63-C53E-4EF9-AEF0-CC1F82EDA7C3">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D860A1B6-8D5E-4FE4-9EDB-4E1397B29BBD"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/04F5EE18-51BD-4A42-A9E7-52826EE0EA8B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:553A6608-733A-477E-BDCB-F0D16F1054E3">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/093D1F2A-587E-4B3C-AAF4-10347561D8A9"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/E4072F00-AC18-479B-BBF5-FE87E12CA45B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6ECE2E9A-54C4-4507-95A6-2F4053719529">
    <ao:context rdf:resource="urn:domeoclient:uuid:CF873305-5222-4D37-9C71-925D3C390B7A"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:D829A856-ADE0-4E82-B940-6DE74589EFC8</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:09:51 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A5707CC-D3AC-4807-9E98-6536CDC7AC55">
    <pav:createdOn>2014-07-13 12:41:59 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:645C5A96-70FA-4A0B-86EC-B070C4FE123F</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:0DDFAFFA-5DE6-4D3B-BC30-6421E6531AD8"/>
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D909BDC5-468E-434E-B3E5-632F1565E73C">
    <ao:suffix> (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance.</ao:suffix>
    <ao:exact>ulfamethazine</ao:exact>
    <ao:prefix> displaces each other from plasma binding sites. High therapeutic concentrations of s</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D909BDC5-468E-434E-B3E5-632F1565E73C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>D909BDC5-468E-434E-B3E5-632F1565E73C</domeo:uuid>
    <pav:createdOn>2014-07-13 11:11:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6887274E-F614-42FD-904F-B7E202949297">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> is 90%, and that of its major metabolite, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>6887274E-F614-42FD-904F-B7E202949297</domeo:uuid>
    <ao:suffix>, is 77%. Neither risperidone nor 9-hydroxyrisperidone displaces each other from plasma binding sites. High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in th</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6887274E-F614-42FD-904F-B7E202949297"/>
    <pav:createdOn>2014-07-13 11:11:10 -0400</pav:createdOn>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8c1ff42287b3489e92d2de3fed3fb66d">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:181381FE-800A-4970-81D8-2B14B7735770">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/BAE41BF7-CAA3-4865-832D-24EB9699E14C"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/8FE58707-AFDD-4F32-9EA8-03EC3BF4D67B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8186AE14-85DE-4E1A-B5F4-BC58233DC47B">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:43E08535-8340-472C-92D9-100ECFA2CB93"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndc3c3e907fd449d6886675778e001295">
    <domeo:sets rdf:resource="urn:pddi:uuid:D7F3CF4B-F577-4BF7-B88B-B5D04D01A04A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D7F3CF4B-F577-4BF7-B88B-B5D04D01A04A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9A220CC1-B0E4-46E3-92ED-BA102CB9A99F"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1dedc17cc1ff4d1c8dc93f32fadfb815">
    <domeo:sets rdf:resource="urn:pddi:uuid:FC76D7A1-BCF3-4AF0-92CC-E5D2F09F6BD7"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/5A962BFF-E73B-4290-B642-C49A7EBCD1B8">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>serotonin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/1311214</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9b55efd2c5c74419aa56dbb74fb7cb53">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nda74ddd69b384cc3bb0e9e283e5dbc9f">
    <domeo:sets rdf:resource="urn:pddi:uuid:8186AE14-85DE-4E1A-B5F4-BC58233DC47B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd2d9ecce81a44c7db8a676dec92c7e46">
    <domeo:sets rdf:resource="urn:pddi:uuid:01E43715-3610-4176-8FB9-E2D7C94F6C63"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1f266d2bcef44243b32a72d28605a5ee">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb929a74c378148db97fc9d4734a3edf3">
    <domeo:sets rdf:resource="urn:pddi:uuid:0CE6C620-40B4-4E55-8185-8A319ECD6D71"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N56cdd45116ba42378521833b6c383a2e">
    <domeo:sets rdf:resource="urn:pddi:uuid:114406CD-55D0-459D-A4F0-CEDB09E201C6"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9f211c81ec6a4639b9f04a0c4176de45">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N05b636d8cede42a9979895e21bc8a8af">
    <domeo:sets rdf:resource="urn:pddi:uuid:9B027AFC-3BAE-4FDC-889F-813F2AD35C5A"/>
  </rdf:Description>
</rdf:RDF>
